FINAL Programme
We gratefully acknowledge the support of our dedicated sponsors:
Table of Contents

2 WELCOME TO QUEBEC CITY
3 Committees
5 Conference Objectives & Information
9 About Quebec City
11 Useful Information
12 Social Programme
13 Instructions to Oral and Poster Presenters
14 Invited Faculty
15 Invited Speakers
16 Travel Awards

17 DETAILED PROGRAMME
19 Sunday, May 27
27 Monday, May 28
37 Tuesday, May 29
43 Index of Presenters
51 Delegate Directory
Welcome to Quebec City

Dear Colleagues,

On behalf of the Organizing Committee, it is our great pleasure to welcome you to join the 6th biennial Canadian Conference on Ovarian Cancer Research (CCOCR).

We believe that this conference will build upon the tremendous momentum generated by previous meetings of this group in Ottawa, Vancouver, Montreal and Toronto, each of which has been designed to further the vision of our initial Conference Chair Dr. Barbara Vanderhyden, of an integrated and multidisciplinary ovarian cancer research community within Canada.

Our meeting features renowned Canadian and International researchers who will present their findings in symposia ranging from biomarker discovery and validation using high-throughput technologies, new concepts for ovarian cancer initiation and progression, genetics and epigenetics studies and their application for novel therapies, and current and emerging clinical trials for ovarian cancer. Additional oral and poster presentations on these themes were selected from the submitted abstracts. The main conference is preceded by an interactive one-day workshop for trainees and a day workshop for survivors.

Following the tradition of the previous meetings, this national conference represents an excellent opportunity for the dissemination, discussion and debate of the new medical and scientific information for ovarian cancer treatment and care. We hope that you will have the chance to present your own data, network, find new collaborators and witness the capacity-building of our growing community by inspiring graduate students and other learners to pursue their professional goals as researchers in ovarian cancer!

We thank you very much for your participation in CCOCR 2012 and wish you a very warm welcome to Quebec City!

Marie Plante M.D.
Conference Co-chair
Gynecologic Oncologist
L'Hôtel-Dieu de Québec, Centre hospitalier universitaire de Québec

Dimcho Bachvarov Ph.D.
Conference Co-chair
Professor
Université Laval
CHUQ-Centre de recherche

Elisabeth Ross MH.Sc.
Honorary Co-Chair
CCOCR 2012
Chief Executive Officer
Ovarian Cancer Canada
Committees

LOCAL ORGANIZING COMMITTEE
Dr. Marie Plante, M.D., Université Laval, Conference Co-chair
Dr. Dimcho Bachvarov, Ph.D., Université Laval, Conference Co-chair
Ms. Elisabeth Ross, M.HSc., Chief Executive Officer, Ovarian Cancer Canada, Honorary Co-chair

Members of the Onco-Gynecology Group for Translational Cancer Research at the CHUQ-Cancer Research Centre at the Hospital Hôtel-Dieu de Québec:
Dr. Jean Grégoire, M.D., Université Laval
Dr. Marie-Claude Renaud, M.D., Université Laval
Dr. Isabelle Bairati, M.D., Ph.D., Université Laval
Dr. Pierre Douville, Ph.D., Université Laval

Other members:
Dr. Anne-Marie Mes-Masson, Ph.D., Université de Montréal
Dr. Patricia Tonin, Ph.D., McGill University
Dr. Walter Gotlieb, M.D., Ph.D., McGill University, SMPD Jewish General Hospital
Dr. Alain Piché, M.D., Université de Sherbrooke

NATIONAL ADVISORY COMMITTEE
Dr. Walter Gotlieb, M.D., Ph.D., McGill University, SMPD Jewish General Hospital
Dr. David Huntsman, M.D., University of British Columbia
Dr. Michelle Letarte, Ph.D., Hospital for Sick Kids
Dr. Helen Mackay, M.D., Division of Hematology/Oncology, UHN, Princess Margaret Hospital
Dr. Anne-Marie Mes-Masson, Ph.D., Université de Montréal
Dr. Dianne Miller, M.D., Reproductive Endocrinology & Infertility, B.C. Women’s Hospital
Dr. Joan Murphy, M.D., University of Toronto
Dr. Brad Nelson, Ph.D., B.C. Cancer Agency
Dr. Diane Provencher, M.D., CHUM - Hôpital Notre-Dame
Dr. Jeremy Squire, Ph.D., Queen’s University
Dr. Helen Steed, M.D., University of Alberta
Dr. Barbara Vanderhyden, Ph.D., University of Ottawa

**ABSTRACT REVIEW COMMITTEE**

Dr. Dimcho Bachvarov, Ph.D., Université Laval, Conference Co-chair
Dr. Isabelle Bairati, M.D., Ph.D., Université Laval
Dr. Marcus Bernardini, M.D., University Health Network
Dr. Blake Gilks, M.D., University of British Columbia
Dr. Walter Gotlieb, M.D., Ph.D., McGill University, SMPD Jewish General Hospital
Dr. Jean Grégoire, M.D., Université Laval
Dr. Martin Köbel, M.D., University of Calgary
Dr. Michelle Letarte, Ph.D., Hospital for Sick Kids
Dr. Anne-Marie Mes-Masson, Ph.D., Université de Montréal
Dr. Dianne Miller, M.D., Reproductive Endocrinology & Infertility, BC Women’s Hospital
Dr. Alain Piché, M.D., Université de Sherbrooke
Dr. Marie Plante, M.D., Université Laval, Conference Co-chair
Dr. Diane Provencher, M.D., CHUM - Hôpital Notre-Dame
Dr. Patricia Shaw, M.D., University of Toronto
Dr. Trevor Sheperd, M.D., University of Western Ontario
Dr. Patricia Tonin, Ph.D., McGill University
Conference Objectives & Information

CONFERENCE OBJECTIVES
The CCO CR has a broad mandate to cover all topics related to ovarian cancer including fundamental, translational, clinical, epidemiological, and psycho-social research. Participants include scientists, clinical researchers, graduate students, fellows and residents from across Canada.

The objectives of the conference are:
1. To bring together researchers with interests in basic, clinical, sociologic and epidemiologic studies in ovarian cancer across Canada in order to increase information dissemination and promote identification of the most innovative findings and pressing questions in ovarian cancer.
2. To facilitate networking and collaboration across the country and encourage the participation of trainees, including residents, graduate students and postdoctoral fellows in ovarian cancer research.
3. To survey the clinical trials being planned or in progress for ovarian cancer patients in Canada, and to learn about translational research projects that have the potential to feed into clinical trials.

CONFERENCE INFORMATION

Abstracts
All abstracts are available in the “Programme” section of the website under the individual day tabs.

Business Centre
The business centre is located in the main lobby area, at the Concierge desk. It will be able to handle your requests for photocopies, faxes, printing, etc. The business centre is accessible 24-hours. If closed, please refer to the front desk clerk.

CME Credits
Accreditation for this event is provided through The Society of Obstetricians and Gynecologists of Canada (SOGC).

This event is an accredited group learning activity under section 1 as defined by the Maintenance of Certification programme of the Royal College of Physicians and Surgeons of Canada.
Programme number: 00274
The following credit hours can be claimed (one credit per hour):

- May 27 7 hours
- May 28 7 hours
- May 29 5 hours

An evaluation form is in your delegate bag. Please return it to the registration desk at the end of the conference. CME Certificates must be requested at the registration desk.

**Conference Evaluation**
A Conference evaluation form is included in your delegate bag. Please complete it and drop it off at the registration desk at the end of the conference. The Committee appreciates your constructive feedback.

**Delegate Hospitality**
A notepad and pen are included in your delegate bag for your convenience. Quebec City maps and guidebooks are available at the registration desk.

**Environmental Considerations**
We incorporated the following considerations into the planning of this conference:

- Online abstract review requiring no printing
- Online registration system requiring no printing
- E-mail marketing requiring no printing
- Water and juice pitchers instead of bottled drinks
- Reduction of print materials by posting abstracts online
- Wireless Internet service for all participants instead of providing a USB key

The hotel is a 4 green key’s property, which means that it has shown national industry leadership and commitment to protecting the environment through wide ranging policies and practices. The hotel has mature programs in place that involve management, employees, guests, and the public, and which have shown substantial and measurable results.

**Emergency/First Aid**
For any emergency or first aid services inside the Château Laurier Hotel, please dial “0” for the operator from any available house phone.
Information
Should you require any assistance during the Conference, please call the registration desk via the hotel operator at 1-877-522-8108. The registration desk will be in service for the duration of the Conference.

Internet Access
Wireless Internet is available throughout the meeting space and in the guestrooms. The access information is available at the registration desk and on tent cards in the Plenary.

Lost and Found
Any lost and found items will be held at the registration desk for the duration of the event. For any unclaimed items after the Conference, please contact IS Event Solutions at info@iseventssolutions.com

Luggage
During the CCOCR Conference, whether you are staying at the Château Laurier Hotel or at a different hotel, you can leave your suitcases with the concierge. The conference organizers do not accept liability for any luggage left unattended and will not store any suitcases at the registration desk.

Meals and Refreshments
Coffee breaks will be served daily in the morning and afternoon in the Foyer Des Plaines. For times of service, please refer to the detailed programme section.

A light breakfast will be available in the poster area (Grand-Allée room & Abraham Martin room) every morning. Please give yourself sufficient time to transfer from the poster area to the meeting room.

Lunch will be served in the poster area (Grande-Allée room & Abraham Martin room) on Monday and Tuesday.

Poster Area and Poster Sessions
Posters are installed in Grande-Allée room & Abraham Martin room, and will be on display for the duration of the Conference.

Poster sessions are scheduled as follows:

<table>
<thead>
<tr>
<th>Session</th>
<th>Date</th>
<th>Time</th>
<th>(presenters at posters as of)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>May 27</td>
<td>17:40-20:00</td>
<td>18:00</td>
</tr>
<tr>
<td>II</td>
<td>May 28</td>
<td>11:30-13:30</td>
<td>12:00</td>
</tr>
<tr>
<td>III</td>
<td>May 29</td>
<td>12:30-14:30</td>
<td>13:00</td>
</tr>
</tbody>
</table>
**Best Trainee Presentation Awards**
The review committee will visit posters of all trainees on the assigned days. Presenters shall thus make sure to be present at their poster at the time indicated on the confirmation letter (on page 7). The poster award winners as well as oral communication award winners will be announced in the Closing Session on Tuesday, May 29 at 15:45. Please plan on staying until the end of that session.

**Public Notice**
The Hotel specifically and all Quebec public spaces in general are smoke-free environments. Smoking is permitted only outside of buildings.

**Registration**
For identification and security purposes, delegates must wear their name badges at all times when onsite at the Château Laurier Hotel and during the Dine-Around.

**Registration & Information Desk Hours**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, May 26</td>
<td>11:00-12:30</td>
<td>Registration Trainee Day (at CRCEO building)</td>
</tr>
<tr>
<td>Sunday, May 27</td>
<td>11:00-17:00</td>
<td></td>
</tr>
<tr>
<td>Monday, May 28</td>
<td>07:00-17:30</td>
<td></td>
</tr>
<tr>
<td>Tuesday, May 29</td>
<td>07:00-17:30</td>
<td></td>
</tr>
</tbody>
</table>

CRCEO Address: 6 McMahon Street, Quebec, QC, G1R 3S2

**Tours**
Should you be interested in obtaining information on guided tours, please make arrangements with the concierge of the hotel.
About Quebec City

Quebec City has everything a city needs to welcome visitors and keep them coming back for more. It is a favorite destination for vacations, conferences, and business and incentive trips, with world-class tourism facilities that offer visitors all the modern conveniences and comforts of city living.

Quebec City at a Glance

- Founded in 1608 by Samuel de Champlain
- Cradle of French civilization in North America
- Capital city of a province of 7.5 million people
- A UNESCO World Heritage Site since 1985 thanks to historic Old Quebec
- Seat of the province’s National Assembly
- 9,000 km² in area, 250 km northeast of Montreal, Population: 632,000 (Greater Quebec City Area)

Quebec City Activities

Just a few steps away, visitors flock to Old Quebec. This fortified part of the city exudes Old World charm, with winding, cobblestoned streets and a profusion of boutiques, museums, and attractions. Take a picture in front of the most photographed hotel in the world, the Château Frontenac and stroll along the Dufferin Terrace overlooking the St-Lawrence river. Go back in time by walking through Place Royale where Samuel de Champlain founded his first “habitation” in 1608 and it is a must to go through le Petit-Champlain district… You will then see why the UNESCO designated Old Quebec as a world heritage treasure!

Also not to be missed:

- A visit to The Citadel, a key part of the city’s fortifications (why go to China, when you can walk a great wall right here). The star-shaped Citadel showcases Quebec’s military history.
- A walk in the Plains of Abraham, where Canada was born after the battles between the French and the English forces in 1759!
- And get to know the men and women who have left their mark on Quebec’s political history by taking a tour of the Parliament Building.

The art lover will also be spoiled by enjoying the Manif d’art 6, The Quebec City Biennial, from May 3 to June 3. This contemporary visual art event gathers over 60 regional and international artists around a central theme. Projects will be presented in diverse locations throughout the city.
Visit the Musée national des beaux-arts du Quebec with their “Open Air - The New Pleinarisme” exhibition, or enjoy the Musée de la Civilisation with their “Hats off! A Tribute to Creativity” or the “Samurai: Masterworks from the Ann and Gabriel Barbier-Mueller Collection” exhibitions.

Don’t forget, Quebec City is renowned for the quality of its fine dining and has a little black book’s worth of local and European-style restaurants, sidewalk cafés, and cool bistro's where you can enjoy local produce, fine cuisine, and innovative global fare, including no fewer than 100 memorable restaurants in the historic old city alone. Bon appétit!

For more information, please go to www.quebecregion.com or pay a visit to the hotel Concierge desk!
Useful Information

Climate
Long, bright, sunny days are expected at this time of year in Quebec City. Average daytime high temperatures are in the low 20°’s C (low 70°’s F), while evening temperatures can be as low as 8-10° C (50° F). A sports jacket or light coat is recommended. The meeting facilities and guest rooms are equipped with air-conditioning.

Credit Cards
In order to report lost or stolen credit cards, these numbers will provide assistance:
- American Express 1-800-268-9824
- Mastercard 1-800-307-7309
- Visa 1-800-847-2911

Dress Code
The dress code during the Conference is casual.

Getting Around in Quebec City
The hotel is conveniently located between New- & Old-Quebec. The best way to explore Upper Town & Lower Town is on foot. In Old-Quebec, if not by foot, we suggest that you travel with the Ecolobus, for only 1$ / passage. This electric bus is custom-made for a district like Old-Quebec. With an average of 50,000 daily passages by locals and tourists, the Ecolobus reduces traffic density, gaz emissions and sound pollution. The Quebec City Public Transit (local buses) is also accessible. You can buy a 1-day pass at $7, a 2-day pass at $11.50 or a 7-day pass at $26. The single rate is $3, cash only.

If you need to travel in surrounding areas, we suggest that you consult the Concierge desk or the following link, as there are many options available:
www.quebecregion.com/en/transportation?a=vis
SOCIAL Program

Sunday, May 27  
17:40 to 20:00  
Welcome Reception  
Hotel Château Laurier. Grande Allée room & Abraham Martin room  
Dress Code: Business-casual  
(included in full registration fee for all participants)

An exciting evening awaits as the Conference officially opens with appetizers and beverages. Come and network with your colleagues to set the tone for the meeting. The first poster session of the conference will take place at the same time! Exciting door prices await!

Monday, May 28  
19:00 to 23:00  
Social Evening  
Montcalm district  
Dress Code: Business-casual

Departure by 19:00 sharp from hotel lobby; please arrive in lobby at 18:45; Participants must write their name on the group lists which are posted in the registration area. Comfortable footwear is recommended (pre-reservation fee of $25 if reserved pre-conference; each additional guest ticket costs $85)

A fun and exciting new concept for this year’s Social Monday! The CCOCR 2012 Local Organizing Committee invites you to the trendy Montcalm Quartier where fine cuisine meets a thrilling nightlife!

Discover where local Quebecers eat by touring 3 of the hottest restaurants in Quebec City:  
• Café Sirocco  
• Le Graffiti  
• La Scala

Walk on Cartier Street, taste great food, network with other delegates while enjoying friendly, fun and knowledgeable service! We are looking forward to seeing you there!

Be prepared to discover, arouse your palette and just have fun!
Instructions for Oral and Poster Presenters

Oral Abstract Presenters
Speakers must check-in and submit their PowerPoint 2012 for Windows presentations at least three hours prior to their presentation. We have assigned two computers for presenters to upload and preview their slides.

These computers are installed in the registration area. You will be required to provide your presentations on USB key.

Note to Macintosh PowerPoint users: Please test your presentation on a Windows XP- or Seven-based computer well prior to attending the meeting to ensure it is functioning properly. (Font substitutions, sizing and loss of pictures/videos may require correction).

Our Scientific Manager, Sabina Schamer, will review your slides with you to ensure that all fonts and videos are functional. She will then keep one copy of your PPT file on the computer and transfer it to the session room computer.

Please check-in with the technician in the meeting room at the break before your session to verify your presentation one last time, to review slide advancement, microphone, etc.

Please note that all presentations will be deleted from all computers at the end of the day.

INDIVIDUAL LAPTOP COMPUTERS ARE NOT PERMITTED FOR PRESENTATIONS!

Poster Presenters
Poster presenters should mount their posters in the designated poster area (Grande Allée & Abraham Martin) between 11:00-15:00 on Sunday, May 27, and remove no later than 16:30 on Tuesday, May 29. Conference staff is available at the registration desk. Velcro will already be attached to your board when you arrive.

Any posters that are not taken down by 17:00 on Tuesday, May 29, will be taken down by Conference staff. Posters unclaimed by 17:30 on Tuesday, May 29, will be discarded.
Invited Faculty

Ronald D. Alvarez, University of Alabama, Birmingham, AL, United States
Dimcho R. Bachvarov, Laval University, Quebec, QC, Canada
Ian G. Campbell, Peter MacCallum Cancer Centre, Melbourne, Australia
Walter H. Gotlieb, McGill University / SMD Jewish General Hospital, Montreal, QC, Canada
David G. Huntsman, University of British Columbia, Vancouver, BC, Canada
Robert J. Kurman, Johns Hopkins Hospital, Baltimore MA, United States
Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
Anne-Marie Mes-Masson, Institut du Cancer de Montréal, Montreal, QC, Canada
Honami Naora, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Kenneth P. Nephew, Indiana University School of Medicine, Indianapolis, IN, United States
Amit M. Oza, Princess Margaret Hospital, Toronto, ON, Canada
Janet A. Sawicki, Thomas Jefferson University, Philadelphia, PA, United States
Moshe Szyf, McGill University, Montreal, QC, Canada
Patricia N. Tonin, McGill University, Montreal, QC, Canada
Barbara Vanderhyden, University of Ottawa, Ottawa, ON, Canada
Invited Speakers

1. Integrating High-throughput Technologies in the Quest for Effective Biomarkers for Ovarian Cancer Prognosis and Therapy
   
   Guest speakers:
   - Dr. Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States
   - Prof. Ian G. Campbell, Peter MacCallum Cancer Centre, Melbourne, Australia
   - Dr. Patricia N. Tonin, McGill University, Montreal, QC, Canada

2. New Concepts in Understanding Ovarian Cancer Initiation and Progression
   
   Guest speakers:
   - Dr. Robert J. Kurman, Johns Hopkins Hospital, Baltimore MA, United States
   - Dr. Honami Naora, The University of Texas MD Anderson Cancer Center, Houston, TX, United States
   - Dr. Barbara Vanderhyden, University of Ottawa, Ottawa, ON, Canada

3. Targeted Therapies and Current and Emergent Clinical Trials
   
   Guest speakers:
   - Dr. David G. Huntsman, University of British Columbia, Vancouver, BC, Canada
   - Dr. Janet A. Sawicki, Thomas Jefferson University, Philadelphia, PA, United States
   - Dr. Ronald D. Alvarez, University of Alabama, Birmingham, AL, United States
   - Dr. Walter H. Gotlieb, McGill University / SMPD Jewish General Hospital, Montreal, QC, Canada

4. Ovarian Cancer Genetics and Epigenetics: from the Lab to the Clinic
   
   Guest speakers:
   - Dr. Kenneth P. Nephew, Indiana University School of Medicine, Indianapolis, IN, United States
   - Dr. Moshe Szyf, McGill University, Montreal, QC, Canada
   - Dr. Dimcho R. Bachvarov, Université Laval, Quebec, QC, Canada
   - Dr. Amit M. Oza, Princess Margaret Hospital, Toronto, ON, Canada

The Barbara J. Murchie Lecture: Translational discOVARIES through Interdisciplinary Research

Dr. Anne-Marie Mes-Masson, Institut du Cancer de Montréal, Montreal, QC, Canada
Travel Awards

The following individuals have been selected for a travel award due to their outstanding abstract quality:

Rania Chehade, University of Toronto, Toronto, ON, Canada
Sally Davis, Peter MacCallum Cancer Centre, Melbourne, Australia
Lena Dolman, McGill University, Montreal, QC, Canada
Tomer Feigenberg, University of Toronto, Toronto, ON, Canada
Hubert Fleury, CRCHUM / ICM, Montreal, QC, Canada
Panagiota Giannakouros, Université de Sherbrooke, Sherbrooke, QC, Canada
Nadzeya Goncharenko Khaider, Université de Sherbrooke, Sherbrooke, QC, Canada
Bao Kong, University of Ottawa & Ottawa Hospital Research Institute, Ottawa, ON, Canada
Melissa McConechy, University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada
Anca Milea, University Health Network, Toronto, ON, Canada
Joel Moody, Samuel Lunenfeld Research Institute, Toronto, ON, Canada
Teresa Peart, University of Western Ontario, London, ON, Canada
Charlène Rico, Faculté de Biomédecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada
Kerri Smith, Memorial University, Saint-John’s, NL, Canada
Dominique Trudel, Toronto General Hospital, University Health Network, Toronto, ON, Canada
Mina Wesa, Gyn/Obs, Division of Gyn Oncology, UBC and BCCA, Vancouver, BC, Canada
Kimberly Wiegand, BCCA and University of British Columbia, Vancouver, BC, Canada
DETAILED PROGRAMME
SUNDAY, MAY 27

13:30-13:35
WELCOME REMARKS FROM THE CO-CHAIRS
Dr. Dimcho Bachvarov, Université Laval, Quebec, QC, Canada
Dr. Marie Plante, Université Laval, Quebec, QC, Canada

13:35-17:00
SYMPOSIUM I
INTEGRATING HIGH-THROUGHPUT TECHNOLOGIES IN THE QUEST FOR EFFECTIVE BIOMARKERS FOR OVARIAN CANCER PROGNOSIS AND THERAPY
Co-Chairs: Blake Gilks, University of British Columbia, Vancouver, BC, Canada
Alain Piché, Université de Sherbrooke, Sherbrooke, QC, Canada

13:35-14:00
INTEGRATED GENOMIC ANALYSES FOR INDIVIDUALIZED OVARIAN CANCER CARE
Douglas A. Levine, M.D., FACOG, FACS, Sloan-Kettering Institute for Cancer Research, New York, NY, United States

14:00-14:30
IDENTIFICATION OVARIAN CANCER DRIVER GENES THROUGH INTEGRATED SNP, EXPRESSION, NEXT GENERATION SEQUENCING AND FUNCTIONAL ANALYSES
Ian G. Campbell, Ph.D., Peter MacCallum Cancer Centre, Melbourne, Australia

14:30-15:00
PERSPECTIVES ON INTERROGATING GENOME-WIDE TRANSCRIPTOMES FROM A UNIQUE GENETICALLY MODIFIED OVARIAN CANCER CELL LINE MODEL WITH HIGH-GRADE SEROUS OVARIAN CARCINOMAS
Patricia N. Tonin, Ph.D., McGill University, Montreal, QC, Canada

15:00-15:15
COFFEE BREAK

15:15-17:00
OC-01
SELECTED ORAL PRESENTATIONS FROM SCIENTIFIC ABSTRACTS

OC-01.01
GENOMIC AND FUNCTIONAL ANALYSIS OF AMPLIFICATION IN HIGH-GRADE SEROUS AND ENDOMETRIOID OVARIAN CANCER IDENTIFIES NOVEL ONCOGENIC DEPENDENCIES THAT MAY BE TARGETED IN THE TREATMENT OF ADVANCED TUMOURS
Sally Davis 1; Kaylene Simpson 2; Ian Campbell 1; Kylie Gorrige 1
1Peter MacCallum Cancer Centre; 2Victorian Centre for Functional Genomics; Melbourne, Australia
OC-01.02 MUTATIONAL PROFILING OF OVARIAN AND ENDOMETRIAL CARCINOMAS REVEALS DISTINCT ALTERATIONS TO IMPROVE CLASSIFICATION
Melissa K. McConeney 1; Kimberly Wiegand 1; Jiarui Ding 2; Martin Hirst 3; Sohrab Shah 2; Cheng-Han Lee 4; Blake C. Gilks 5; Paul Goodfellow 5; David G. Huntsman 1
1University of British Columbia, BC Cancer Agency, Vancouver, BC, Canada; 2University of British Columbia, BC Cancer Research Centre, Vancouver, BC, Canada; 3University of British Columbia, CHiBi, Vancouver, BC, Canada; 4University of British Columbia, Vancouver General Hospital, Vancouver, BC, Canada; 5Washington University, St. Louis, MO, United States

OC-01.03 SPECIFIC RETINOBLASTOMA (RB) PATHWAY ALTERATIONS DEFINE CLINICAL OUTCOME IN HIGH GRADE SEROUS CARCINOMA (HGSC)
Anca Milea 1; Sophia George 2; Hal Berman 3; Mona Gauthier 4; Patricia Shaw 5
1UHN, University of Toronto, Department of Laboratory Medicine and Pathobiology; 2UHN, The Campbell Family Institute of Breast Cancer Research; 3UHN, The Campbell Family Institute of Breast Cancer Research, Department of Laboratory Medicine and Pathobiology; 4The Campbell Family Institute of Breast Cancer Research, Department of Medical Biophysics; 5UHN, Department of Laboratory Medicine and Pathobiology; Toronto, ON, Canada

OC-01.04 MOLECULAR PROFILING OF PRIMARY MUCINOUS TUMOURS OF THE OVARY
Sally Hunter 1; Georgie Ryland 1; Maria Doyle 1; Simone Rowley 1; Michael Christie 2; Kylie Gorringe 1; Ian Campbell 1
1Peter MacCallum Cancer Centre; 2Ludwig Institute of Cancer Research; Melbourne, Victoria, Australia

OC-01.05 ABSENCE OF ARID1A-ASSOCIATED PROTEIN EXPRESSION (BAF250) IS ASSOCIATED WITH INCREASED PAKT PHOSPHORYLATION INDEPENDENT OF PIK3CA MUTATION STATUS IN CLEAR CELL AND ENDOMETRIOID OVARIAN CANCERS
Mark Carey 2; Kim Wiegand 2; Blake Gilks 3; Steve Kalloger 2; Yiling Lu 4; Sarah Finlayson 1; Katherine Stemke-Hale 4; Bryan Hennessy 2; Gordon Mills 4; David Huntsman 2
1Vancouver Coastal Health and BC Cancer Agency, Vancouver, BC, Canada; 2BC Cancer Agency, Vancouver, BC, Canada; 3Vancouver Coastal Health, Vancouver, BC, Canada; 4MD Anderson Cancer Center, Houston, TX, United States; 5Beaumont Hospital, Dublin, Ireland

OC-01.06 REACTOME – LINKING PATHWAYS, NETWORKS AND CANCER
Robin Haw 1; Marija Orlic-Milacic 1; Karen Rothfels 1; Guanming Wu 1; Reactome Team 1; Henning Hermjakob 2; Peter D’Eustachio 3; Lincoln Stein 1
1OICR, Toronto, ON, Canada; 2EBI, Hinxton, United Kingdom; 3NYUMC, New York, NY, United States
**OC-01.07**

**EXPRESSION OF VGLL3 IS ASSOCIATED WITH A TUMOUR SUPPRESSOR PHENOTYPE IN EPITHELIAL OVARIAN CANCER**

Karen Gambaro; Michael C.J. Quinn; Paulina Wojnarowicz; Manon de Ladurantaye; Kim Leclerc Décaulniers; Véronique Barres; Diane M. Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N. Tonin

1Department of Human Genetics, McGill University, Montreal, QC, Canada; 2Centre de recherche du Centre hospitalier de l’Université de Montréal / Institut du cancer de Montréal, Montreal, QC, Canada; 3Centre de recherche du Centre hospitalier de l’Université de Montréal /Division de gynécologie oncologique, Montreal, QC, Canada; 4Centre de recherche du Centre hospitalier de l’Université de Montréal / Institut du cancer de Montréal / Department of Medicine, Montreal, QC, Canada; 5The Research Institute of McGill University Health Centre / Department of Surgery, Urology Division, McGill University, Montreal, QC, Canada; 6Department of Human Genetics and Medicine, McGill University / The Research Institute of McGill University Health Centre, Montreal, QC, Canada

---

**17:00-17:40**

**THE BARBARA J. MURCHIE LECTURE: TRANSLATIONAL DISCOVARIETIES THROUGH INTERDISCIPLINARY RESEARCH**

Anne-Marie Mes-Masson, Ph.D., Institut du cancer de Montréal, Montreal, QC, Canada

---

**17:40-20:00**

**OPENING RECEPTION AND POSTER SESSION I**

GENOMIC S, EPIGENOMIC S, PROTEOMIC S, MICROARRAY AND BIOMARKER STUDIES, NEW PLATFORMS FOR DISCOVERY, MOLECULAR SIGNATURES OF TUMOR CELLS, BIOINFORMATICS

**P.01**

**BTN3A2 EXPRESSION IN EPITHELIAL OVARIAN CANCER IS ASSOCIATED WITH HIGHER TUMOR INFILTRATING T CELLS AND A BETTER PROGNOSIS**

Cécile Le Page; Alexandre Marineau; Patrick Bonza; Kurosh Rahimi; Louis Cyr; Jason Madore; Nathalie Delvoye; Anne-Marie Mes-Masson; Diane Provencher; Jean-François Cailhier

Centre de recherche du Centre hospitalier de l’Université de Montréal / Institut du cancer de Montréal, Montreal, QC, Canada

**P.04**

**CYTOKINE PROFILING OF HUMAN EPITHELIAL OVARIAN CANCER ASCITES**

Isabelle Matte; Denis Lane; Claude Laplante; Claudine Rancourt; Alain Piché

1Université de Sherbrooke; 2Centre hospitalier universitaire de Sherbrooke; Sherbrooke, QC, Canada

**P.07**

**EXPRESSION AND LOCALIZATION OF PROSTATE APOPTOSIS RESPONSE-4 (PAR-4) DURING OVARIAN TUMOR PROGRESSION**

Parvesh Chaudhry; Mohan Singh; Valerie Leblanc; Sophie Parent; Eric Asselin

Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada
P.10

GENE EXPRESSION PROFILING OF HUMAN MESOTHELIAL CELLS AFTER OVARIAN CANCER ASCITES TREATMENT
Alain Piché 1; Isabelle Matte 1; Claudine Rancourt 1; Dimcho Bachvarov 2
1Université de Sherbrooke, Sherbrooke, QC, Canada; 2Université Laval, Quebec, QC, Canada

P.13

MUTATION ANALYSIS OF CELL LINES DERIVED FROM MATCHED PRIMARY AND RECURRENT EPITHELIAL OVARIAN CANCERS USING NEXT GENERATION SEQUENCING TECHNOLOGY, WITH A FOCUS ON CELL CYCLE RELATED GENES
Guergana Tchakarska 1; Michael Quinn 1; Sohrab Shah 2; Ali Bashashati 2; Karey Shumansky 2; Suzanna Arcand 3; Diane Provencher 4; Patricia Tonin 5; David Huntsman 2; Anne-Marie Mes-Masson 6
1Institut du cancer de Montréal, CRCHUM, Montreal, QC, Canada; 2Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada; 3The Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 4Département d’Obstétrique et Gynécologie, Division of Gynecologic Oncology, Université de Montréal, Montreal, QC, Canada; 5Department of Human Genetics, McGill University, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 6Institut du cancer de Montréal, CRCHUM, Département de Médecine, Université de Montréal, Montreal, QC, Canada

P.16

COMPARISON OF NORMAL REFERENCE CONTROLS USED IN TRANSCRIPTOME ANALYSES OF HIGH GRADE SEROUS OVARIAN TUMOURS
Ashley H. Birch 1; Diane M. Provencher 2; Anne-Marie Mes-Masson 3; Patricia N. Tonin 4
1Department of Human Genetics, McGill University; 2Centre de recherche du Centre hospitalier de l’Université de Montréal, Institut du cancer de Montréal; 3Division of Gynecologic Oncology and Department of Medicine, Université de Montréal; 4Departments of Human Genetics and of Medicine, McGill University, The Research Institute of the McGill University Health Centre; Montreal, QC, Canada

P.19

EMPIRICAL CHEMOSENSITIVITY TESTING USING A MICROFLUIDICS-BASED MULTIPLEX PLATFORM
Tamal Das 1; Liliane Meunier 2; Thomas Gervais 3; Laurent Barbe 4; Olivier Guenat 5; Diane Provencher 6; Anne-Marie Mes-Masson 7
1Institut du cancer de Montréal, CRCHUM; Department of Engineering Physics, École Polytechnique de Montréal, Montreal, QC, Canada; 2Institut du cancer de Montréal, CRCHUM, Montreal, QC, Canada; 3Department of Engineering Physics, École Polytechnique de Montréal, Montreal, QC, Canada; 4Centre Suisse d’électronique et de microtechnique, Neuchâtel, Switzerland; 5ARTORG Center, Medical Faculty, University of Berne, Berne, Switzerland; 6Institut du cancer de Montréal, CRCHUM; Division of Gynecologic Oncology, Université de Montréal, Montreal, QC, Canada; 7Institut du cancer de Montréal, CRCHUM; Département de médecine, Université de Montréal, Montreal, QC, Canada
P.22 MODEL SYSTEMS FOR CANCER AND CONTEXTUAL-GENOMIC RESEARCH: CLEAR CELL CARCINOMA OF THE OVARY
Michael Anglesio 1; Steven Kalloger 2; Kary Schumansky 3; Nataliya Melnyk 1; Christine Chow 2; Clara Salamanca 1; Janine Senz 1; Winnie Yang 4; Sohrab Shah 1; David Huntsman 5
1Department of Pathology and Lab Medicine, UBC; 2GPEC Lab Department of Pathology of VGH and UBC; 3British Columbia Cancer Research Centre, BCCA; 4CTAG, BC Cancer Agency; 5CTAG, BCCA, and Department of Pathology and Lab Medicine, UBC; Vancouver, BC, Canada

P.25 IDENTIFYING KEY GENES MEDIATING THE TUMOUR-PROMOTING ACTIONS OF ESTROGEN IN OVARIAN CANCER
Kendra Hodgkinson 1; Laura Laviolette 1; Carolina Perez-Iratxeta 2; Barbara Vanderhyden 1
1Cellular and Molecular Medicine, University of Ottawa, Ottawa Hospital Research Institute; 2Ontario Genomics Innovation Centre, Ottawa Hospital Research Institute; Ottawa, ON, Canada

P.28 GENOME-WIDE DNA METHYLATION PROFILING OF CPG ISLANDS IDENTIFIES ACTIVITY-REGULATED CYTOSKELETON-ASSOCIATED PROTEIN (ARC) AS A NOVEL HYPMETHYLATION TARGET IN OVARIAN CANCER
Jean-François Pelletier 1; Mamadou Keita 1; Éric Paquet 2; Magdalena Bachvarova 3; Marie Plante 3; Jean Grégoire 2; Marie-Claude Renaud 2; Chantale Morin 4; Dimcho Bachvarov 5
1Department of Molecular Medicine, Université Laval, Lévis, QC, Canada; 2Cancer Research Centre, Hôpital l’Hôtel-Dieu de Québec, Quebec, QC, Canada; 3Department of Obstetrics and Gynecology, Université Laval, Quebec, QC, Canada; 4Department of Pathology, Université Laval, Quebec, QC, Canada; 5Department of Molecular Medicine, Université Laval, Quebec, QC, Canada

P.31 DIFFERENTIAL EXPRESSION OF STEROID HORMONE RECEPTORS IN FALLOPIAN TUBES AND IN OVARIAN SURFACE EPITHELIUM FROM MEXICAN WOMEN
Veronica Diaz-Hernandez 1; Delia Perez-Montiel 2; Martin Cadena-Sandoval 1; Maria Jose Gomora 1; Flavia Morales Vasquez 2; Enrique Pedernera 1; Maria del Carmen Mendez 1
1Universidad Nacional Autonoma de Mexico, Mexico; 2Instituto Nacional de Cancerologia, Mexico

P.34 BREAKPOINT ANALYSIS OF 8 HIGH-GRADE SEROUS OVARIAN CARCINOMAS INDICATES THAT CHROMOSOME 19 TENDS TO HAVE MORE BREAKS THAN EXPECTED
Celia M.T. Greenwood 1; Kathleen Klein Oros 2; Suzanna L. Arcand 3; Diane Provencher 4; Anne-Marie Mes-Masson 4; Patricia N. Tonin 5
1Lady Davis Institute for Medical Research, Department of Oncology, McGill University; 2Lady Davis Institute for Medical Research; 3The Research Institute of the McGill University Health Centre; 4Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; 5The Research Institute of the McGill University Health Centre, Departments of Medicine and Human Genetics, McGill University; Montreal, QC, Canada
P.37  
**VEPH1 IS A NOVEL REGULATOR OF CANONICAL TGF-BETA SIGNALING IN OVARIAN CANCER CELLS**  
Premalatha Shathasivam 1; Alexandra Kollara 1; Carl Virtanen 2; Jeff Wrana 1; Theodore Brown 1  
1Samuel Lunenfeld Research Institute, Mount Sinai Hospital; University of Toronto; 2OCI Microarray Centre; Toronto, ON, Canada

P.40  
**IDENTIFICATION OF MEDIATORS IMPLICATED IN THE METASTATIC PROGRESSION OF OVARIAN CANCER TO PERITONEAL MESOTHELIUM USING HIGH-THROUGHPUT PROTEOMICS**  
Natasha Musrap 1; George S. Karagiannis 1; Ihor Batruch 2; Chris Smith 2; Eleftherios P. Diamandis 2  
1University of Toronto; 2Mount Sinai Hospital; Toronto, ON, Canada

P.43  
**INTEGRATING HIGH-THROUGHPUT TECHNOLOGIES FOR THE IDENTIFICATION AND VALIDATION OF OVARIAN CANCER BIOMARKERS**  
Felix Leung 1; Apostolos Dimitromanolakis 2; Eleftherios P. Diamandis 1; Vathany Kulasingam 1  
1Department of Laboratory Medicine and Pathobiology, University of Toronto; 2Samuel Lunenfeld Research Institute and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; Toronto, ON, Canada

P.46  
**MECHANISMS OF KLK6 EXPRESSION AND BIOMARKER DISCOVERY IN OVARIAN CARCINOMAS: AN INTEGRATED GENOMIC, MIRNA AND PROTEOMIC PROFILING APPROACH**  
Jane Bayani 1; Uros Kuzmanov 1; Ihor Batruch 2; Christopher Smith 2; Punit Saraon 1; William Fung 1; Jeremy A. Squire 3; Eleftherios P. Diamandis 4  
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada; 3Department of Laboratory Medicine and Pathobiology, Queen’s University, Kingston, ON, Canada; 4Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

P.49  
**GLOBAL PROFILING OF DNA METHYLATION IDENTIFIES UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE: POLYPEPTIDE N-ACETYLGLACTOSAMINYLTRANSFERASE 3 (GALNT3) AS A NOVEL HYPMETHYLATION TARGET IN OVARIAN CANCER**  
Zhiqiang Wang 1; Mamadou Keita 1; Eric Paquet 2; Magdalena Bachvarova 2; Marie Plante 3; Jean Gregoire 3; Marie-Claude Renaud 3; Chantale Morin 4; Dimcho Bachvarov 1  
1Department of Experimental Medicine, Université Laval; 2Cancer Research Centre, Hôpital l’Hôtel-Dieu de Québec, Centre hospitalier universitaire de Québec (CHUQ); 3Department of Obstetrics and Gynecology, Université Laval; 4Department of Pathology, Université Laval; Quebec, QC, Canada
SUNDAY, MAY 27

P.52

IN SILICO CANCER DRUG DISCOVERY: CANDIDATE THERAPEUTICS FOR OVARIAN CANCER FROM AN INTEGRATIVE META-ANALYSIS OF CANCER GENE SIGNATURES AND HIGH-THROUGHPUT DRUG RESPONSE DATA

Josh Griesman; Kristen Fortney; Igor Jurisica
Ontario Cancer Institute, Toronto, ON, Canada

P.54

A CANDIDATE GENE SHORT LIST FOR A GRANULOSA CELL TUMOUR SUSCEPTIBILITY GENE (GCT1) IN A SPONTANEOUS MOUSE MODEL OF EARLY-ONSET TUMOURIGENESIS

Kerri Smith 1; Sarah Halfyard 1; Edward Yaskowiak 1; Wesley Beamer 2; Ann Donward 1
1Memorial University, Saint-John’s, NL, Canada; 2The Jackson Laboratory, Bar Harbor, ME, United States
MONDAY, MAY 28

07:30-08:30  CONTINENTAL BREAKFAST IN THE POSTER AREA

08:30-11:30  SYMPOSIUM II

NEW CONCEPTS IN UNDERSTANDING OVARIAN CANCER INITIATION AND PROGRESSION
Co-Chairs:
Diane Miller, British Columbia Women’s Hospital, Vancouver, BC, Canada
Nelly Auersperg, University of British Columbia, Vancouver, BC, Canada

08:30-09:00  PREVENTION OF OVARIAN CANCER BASED ON NEW CONCEPTS OF MOLECULAR PATHOGENESIS AND ORIGIN
Robert J. Kurman, Johns Hopkins Hospital, Baltimore, MA, United States

09:00-09:30  HOMEobox GENES: MOLECULAR LINKAGE BETWEEN EMBRYONIC DEVELOPMENT AND CANCER
Honami Naora, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX, United States

09:30-10:00  OVULATION-ASSOCIATED FACTORS PROMOTE STEM/PROGENITOR CELL CHARACTERISTICS IN OVARIAN SURFACE EPITHELIAL CELLS: A STARTING POINT FOR OVARIAN CANCER?
Barbara Vanderhyden, Ph.D., University of Ottawa, Ottawa, ON, Canada

10:00-10:20  COFFEE BREAK
MONDAY, MAY 28

10:20-11:30

OC-02
SELECTED ORAL PRESENTATIONS FROM SCIENTIFIC ABSTRACTS

OC-02.01
DACHSHUND HOMOLOG 2 REGULATES CELL FATE IN THE FALLOPIAN TUBE DURING THE MENSTRUAL CYCLE
Rania Chehade; Sophia George; Jennifer Cruikshank; Noor Salman; Bernard Martin; Jason Moffat; Troy Ketela; Patricia Shaw; Mona Gauthier; Hal Berman
University of Toronto, Toronto, ON, Canada

OC-02.02
THE LOSS OF HOXA5 FUNCTION CAUSES ESTROUS ACYCLICITY AND OVARIAN EPITHELIAL INCLUSION CYSTS
Lucie Jeannotte; Gaëlle Gendronneau; Olivier Boucherat
Centre de recherche en cancérologie de l’Université Laval, Quebec, QC, Canada

OC-02.03
ASSESSING THE EVOLUTION AND IMMUNOGENICITY OF THE OVARIAN CANCER GENOME
Brad Nelson \(^1\); Mauro Castellarin \(^2\); John Webb \(^1\); Darin Wick \(^1\); Peter Watson \(^1\); Rob Holt \(^2\)
\(^1\)Deelely Research Centre, BC Cancer Agency, Victoria, BC, Canada; \(^2\)Genome Sciences Centre, BC Cancer Agency, Vancouver, BC, Canada

OC-02.04
NOTCH3 ACTIVATION UP-REGULATES GUCY1B3 EXPRESSION IN OVARIAN CANCER AND IMMORTALIZED OVARIAN SURFACE EPITHELIAL CELLS
YangXin Fu; Nidhi Gupta; Ahmed El-Sehemy; Zhihua Xu; Helen Steed
University of Alberta, Edmonton, AB, Canada

OC-02.05
HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AND OVARIAN CANCER PROGNOSIS
Dominique Trudel \(^1\); Isabelle Bairati \(^2\); Bernard Têtu \(^3\); Jean Grégoire \(^4\); Marie Plante \(^4\); Marie-Claude Renaud \(^4\); Dimcho Bachvarov \(^3\); Pierre Douville \(^3\)
\(^1\)Toronto General Hospital, University Health Network, Toronto, ON, Canada; \(^2\)Clinical Epidemiology Unit, Université Laval Cancer Research Center, CHUQ-1’Hôtel-Dieu, Quebec, QC, Canada; \(^3\)Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Quebec, QC, Canada; \(^4\)Department of Gynecology-Obstetrics, 1’Hôtel-Dieu de Québec from the Centre hospitalier universitaire de Québec, Quebec, QC, Canada

11:30-13:30

LUNCH BREAK
MONDAY, MAY 28

12:00-13:30 POSTER SESSION II

PATHOLOGICAL AND CELLULAR STUDIES, DISEASE CLASSIFICATION, STEM CELLS, MODELS OF DISEASE, GENETIC PREDISPOSITION, RISK FACTORS, PREVENTION

P.02 ORGANIZING CELLULAR AND MOLECULAR HETEROGENEITY IN HIGH-GRADE SEROUS OVARIAN CANCER
Jocelyn Stewart 1; Bernd Bodenmiller 2; Laurie Ailles 3; Marcus Bernardini 3; Patricia Shaw 3; Garry Nolan 4; Benjamin Neel 3
1University of Toronto / Ontario Cancer Institute, Toronto, ON, Canada; 2ETH Zurich, Zurich, Switzerland; 3Ontario Cancer Institute, Toronto, ON, Canada; 4Stanford University, Palo Alto, CA, United States

P.05 INTERACTION OF MUC16 (CA125) WITH β-CATENIN
Panagiota Giannakouros; Isabelle Matte; Claudine Rancourt; Alain Piché
Département de Microbiologie et Infectiologie, FMSS, Université de Sherbrooke, Sherbrooke, QC, Canada

P.08 HYPERGLYCEMIA ACCELERATES THE PROGRESSION OF EPITHELIAL OVARIAN CANCER IN MICE, WHICH MAY BE MEDIATED BY ACTIVE SODIUM-GLUCOSE CO-TRANSPORT
Lisa Kellenberger 1; Alison Holloway 2; Jim Petrik 1
1University of Guelph, Guelph, ON, Canada; 2McMaster University, Hamilton, ON, Canada

P.11 CONTRIBUTION OF RECURRENT BRCA2 MUTATIONS AMONG FRENCH CANADIAN OVARIAN CANCER CASES
Lena Dolman 1; Moria H. Belanger 1; Suzanna L. Arcand 2; Zhen Shen 3; George Chong 3; Anne-Marie Mes-Masson 4; Diane Provencer 5; Patricia N. Tonin 6
1Department of Human Genetics, McGill University; 2The Research Institute of the McGill University Health Centre; 3Molecular Pathology Unit, Department of Pathology, Jewish General Hospital, McGill University; 4Département de médecine, Université de Montréal; 5Division de gynécologie oncologique, Université de Montréal; 6Departments of Medicine and Human Genetics, McGill University; The Research Institute of the McGill University Health Centre; Montreal, QC, Canada
P.14

CONTRIBUTION OF RECURRENT BRCA1 MUTATIONS TO OVARIAN CANCER CASES IN THE FRENCH CANADIAN POPULATION OF QUEBEC

Moria H. Bélanger; Lena Dolman; Suzanna L. Arcand; Zhen Shen; George Chong; Anne-Marie Mes-Masson; Diane Provencher; Patricia N. Tonin

1Department of Human Genetics, McGill University; 2The Research Institute of the McGill University Health Centre; 3Molecular Pathology Unit, Department of Pathology, Jewish General Hospital, McGill University; 4Département de médecine, Université de Montréal; Centre de recherche du Centre Hospitalier de l’Université de Montréal; 5Division de gynécologie oncologique, Université de Montréal; Centre de recherche du Centre hospitalier de l’Université de Montréal; 6Departments of Medicine and Human Genetics, McGill University; The Research Institute of the McGill University Health Centre; Montreal, QC, Canada

P.17

ENDOMETRIOSIS IS AN OVARIAN PRECURSOR LESION: THE MUTATIONAL BASIS OF ITS TRANSFORMATION

Alicia Tone; Michelle Woo; Ali Bashashati; Paul Yong; Catherine Allaire; Christina Williams; Sohrab Shah; Blake Gilks; David Huntsman

1University of British Columbia; 2BC Cancer Agency; 3BC Women’s Hospital; Vancouver, BC, Canada

P.20

CHRONIC LOW- GRADE, SYSTEMIC INFLAMMATION ACCELERATES THE PROGRESSION OF EPITHELIAL OVARIAN CANCER (EOC) IN VIVO

Amanda Kerr; Lisa Kellenberger; Jim Petrik

University of Guelph, Guelph, ON, Canada

P.23

INTERACTIONS BETWEEN BRCA1 AND THE IGF-1R SIGNALING PATHWAY IN HUMAN EPITHELIAL OVARIAN CANCER CELLS

Marie-Claude Beauchamp; Amber Yasmeen; Sanaa Iqbal; Laura Drudi; Walter H. Gotlieb

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada

P.26

IMPACT OF RAN GTPASE IN OVARIAN CANCER PROGRESSION

Katia Y. Caceres; Véronique Barres; Euridice Carmona; Patricia Tonin; Diane Provencher; Anne-Marie Mes-Masson

1Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; 2The Research Institute of the McGill University Health Center; Department of Medicine; Department of Human Genetics; 3Division of Gynecologic Oncology, Université de Montréal; Institut du cancer de Montréal, CRCHUM; 4Institut du Cancer de Montréal, CRCHUM; Département de médecine, Université de Montréal; Montreal, QC, Canada
MONDAY, MAY 28

P.29

GERMLINE TP53 MUTATIONS IN BREAST/OVARIAN CANCER FAMILIES OF FRENCH CANADIAN DESCENT

Suzanna Arcand 1; Laura Palma 2; Nora Wong 3; Lidia Kasprzak 4; Anne-Marie Mes-Masson 4; Parviz Ghadirian 5; William Foulkes 6; Diane Provencher 7; Patricia Tonin 8

1 The Research Institute of the McGill University Health Centre; 2Department of Medical Genetics, McGill University Health Centre; 3Department of Medical Genetics, Cancer Prevention Centre, Jewish General Hospital; 4Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Institut du cancer de Montréal; 5Epidemiology Research Unit, Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM); 6Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University; 7Division of Gynecologic Oncology, Université de Montréal; 8The Research Institute of the McGill University Health Centre; Departments of Medicine and Human Genetics, McGill University; Montreal, QC, Canada

P.32

CHARACTERIZATION OF THE RUNX1 AND RUNX2 AS HYPOMETHYLATED GENES IN ADVANCED OVARIAN CANCER: POSSIBLE ROLES IN OVARIAN CANCER PROGRESSION, INVASION/METASTASIS AND CHEMoresistance

Mamadou Keita 1; Dimcho Bachvarov 1; Eric Paquet 2; Magdalena Bachvarova 2; Marie Plante 3; Jean Gregoire 3; Marie-Claude Renaud 3; Chantale Morin 4; Anne-Marie Mes-Masson 5

1Department of Molecular Medicine, Université Laval, Quebec, QC, Canada; 2Cancer Research Centre, Hôpital l’Hôtel-Dieu de Québec, Centre hospitalier universitaire de Québec (CHUQ), Quebec, QC, Canada; 3Department of Obstetrics and Gynecology, Université Laval, Quebec, QC, Canada; 4Department of Pathology, Université Laval, Quebec, QC, Canada; 5Department of Medicine, Université de Montréal, Montreal, QC, Canada

P.35

EXPLORATORY IMMUNOHISTOCHEMICAL INVESTIGATION OF ANAEROBIC GLYCOLYSIS AND ALTERED TUMOR METABOLISM IN OVARIAN CANCER

Jason Madore 1; Steve Kalloger 2; Julie Lorette 3; Samuel Aparicio 4; David Huntsman 3

1Pathology and Lab Medicine, University of British Columbia; 2GPEC, Pathology VGH, University of British Columbia; 3CTAG, BCCA; 4Molecular Oncology BC Cancer Agency, University of British Columbia; 5CTAG, BCCA, Pathology and Lab Medicine, University of British Columbia; Vancouver, BC, Canada

P.38

CHARACTERIZATION OF BOVINE OVIDUCTAL EPITHELIAL CELLS IN CULTURE AND INFLAMMATORY RESPONSE TO FOLLICULAR FLUID EXPOSURE

Angela Lau 1; Alexandra Kollara 1; Elizabeth St. John 2; Alicia Tone 3; Ellen M. Greenblatt 4; W. Allan King 2; Theodore J. Brown 2

1Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Toronto, ON, Canada; 2Department of Bioscience, University of Guelph Veterinary School, Guelph, ON, Canada; 3Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON, Canada; 4Mount Sinai Hospital, Department of Obstetrics and Gynecology, Toronto, ON, Canada
MONDAY, MAY 28

P.44 ANDROGEN RECEPTOR EXPRESSION IN EPITHELIAL STRUCTURES OF THE OVARY IN PERIMENOPAUSE

Maria Del Carmen Mendez 1; Flavia Morales Vasquez 2; Delia Perez-Montiel 2; Veronica Diaz-Hernandez 1; Martin Cadena-Sandoval 1; Maria Jose Gomora 1; Gonzalo Montalvo 2; Enrique Perdernera 1

1Universidad Nacional Autonoma de Mexico, Mexico; 2Instituto Nacional de Cancerologia, Mexico

P.47 TGFβ/BMP SIGNALLING REGULATION OF THE EMT PHENOTYPE IN ASCITES-DERIVED EPITHELIAL OVARIAN CANCER SPHEROIDS

Samah Rafehi; Teresa Peart; Yudith Valdes; Gabriel DiMattia; Trevor Shepherd

The University of Western Ontario, London, ON, Canada

P.50 LOSS OF LKB1 IS AN EARLY EVENT IN HIGH-GRAD E SEROUS CARCINOMA

Sophia H.L. George 1; Anca Milea 1; Mona Gauthier 1; Patricia Shaw 2

1Campbell Family Institute for Breast Cancer Research; 2Campbell Family Institute for Breast Cancer Research / University Health Network; Toronto, ON, Canada

P.53 GLUCOCORTICOID-INDUCED REVERSAL OF INTERLEUKIN-1β (IL-1β)-STIMULATED INFLAMMATORY GENE EXPRESSION IN FALLOPIAN TUBE EPITHELIAL CELLS

Stephanie Backman 1; Alexandra Kollara 1; Carl Virtanen 2; Theodore Brown 1

1University of Toronto; 2OCI Microarray Center; Toronto, ON, Canada

P.55 NODAL ENHANCES MIGRATION AND INVASIVENESS OF EPITHELIAL OVARIAN CANCER CELLS

Christine Zhang (equal contribution) 1; YaoYun Liang (equal contribution) 1; Jackie Feng 1; Zhaogun Deng 2; Burton Yang 2; Chun Peng 1

1Department of Biology, York University; 2Sunnybrook Research Institute, Sunnybrook Health Sciences Centre; Toronto, ON, Canada
P.56

REPORT ON A QUALITY CONTROL EXERCISE PERFORMED ON SPECIMENS FROM CANADIAN BIOBANKS PARTICIPATING IN THE COEUR SPECIMEN REPOSITORY

Manon de Ladurantaye 1; Cécile Le Page 1; Martin Kobel 2; Kurosh Rahimi 3; Jason Madore 1; Sindy Babinszky 4; Dimcho Bachvarov 5; Magdalena Bachvarova 6; Marie-Claude Beauchamp 7; Carol E. Cass 8; Dianne Chadwick 9; Colleen Crane 10; Sambasivarao Damaraju 6; Jennifer Dufour 1; Walter H. Gotlieb 7; Steve E. Kalloger 11; Lise Portelance 1; Jessica N. McAlpine 12; Isabelle Matte 13; Alain Piché 13; Patricia Shaw 1; Barbara C. Vanderhyden 10; Peter H. Watson 1; David G. Huntsman 11; Diane M. Provencher 1; Anne-Marie Mes-Masson 1

1 ICM/CRC-CHUM, Montreal, QC, Canada; 2 Foothills Medical Center, Calgary, AB, Canada; 3 Hôpital Notre-Dame / CHUM, Montreal, QC, Canada; 4 BC Cancer Agency, Victoria, BC, Canada; 5 Université Laval, Quebec, QC, Canada; 6 CRCCHUQ, Montreal, QC, Canada; 7 Segal Cancer Center, Montreal, QC, Canada; 8 Cross Cancer Institute, Edmonton, AB, Canada; 9 PMH/UHN, Toronto, ON, Canada; 10 Ottawa Research Hospital Institute, Ottawa, ON, Canada; 11 Vancouver General Hospital, Vancouver, BC, Canada; 12 University of British Columbia, Vancouver, BC, Canada; 13 Université de Sherbrooke, Sherbrooke, QC, Canada

13:30-18:00

SYMPOSIUM III

TARGETED THERAPIES AND CURRENT AND EMERGING CLINICAL TRIALS

Co-Chairs:
Marie Plante, M.D, Gynecologic Oncology Division, Université Laval, Quebec, QC, Canada
Diane Provencher, M.D., Centre hospitalier de l’Université de Montréal, Montreal, QC, Canada

13:30-14:00

GENOMIC-DRIVEN SUBTYPE SPECIFIC TREATMENT OPPORTUNITIES FOR OVARIAN CANCER

David G. Huntsman, M.D., FRCP, FCCMG, University of British Columbia, Vancouver, BC, Canada; Interim Director, OvCaRe, BC, Canada

14:00-14:30

OVARIAN CANCER NANTHERAPIES

Janet A. Sawicki, Ph.D., Thomas Jefferson University, Philadelphia, PA, United States

14:30-15:00

GENE THERAPY FOR OVARIAN CANCER – FROM BENCH TO BEDSIDE

Ronald D. Alvarez, M.D., University of Alabama, Birmingham, AL, United States

15:00-15:30

SPECIAL LECTURE

INTRODUCING ROBOTIC SURGERY IN OVARIAN CANCER CARE

Walter Gotlieb, McGill University, Montreal, QC, Canada

15:30-15:50

COFFEE BREAK

www.cccor.org
OC-03.01 THROMBOSPONDIN-1 TREATMENT INDUCES REGRESSION OF ADVANCED STAGE EPITHELIAL OVARIAN CANCER AND SIGNIFICANTLY INCREASES DISEASE FREE SURVIVAL
Nicolle Linneith-Petrik 1; James Greenaway 1; Jack Lawler 2; Jim Petrik 1
1University of Guelph, Guelph, ON, Canada; 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States

OC-03.02 A SMALL MOLECULE KINASE INHIBITOR SCREEN TO IDENTIFY NOVEL TREATMENTS FOR CLEAR CELL CARCINOMA
Kimberly Wiegand 1; Arthur V. Sampaio 2; Steve Kalloger 2; Alicia Tone 1; T. Michael Underhill 2; David G. Huntsman 1
1BCCA and The University of British Columbia; 2The University of British Columbia; Vancouver, BC, Canada

OC-03.03 PATHWAYS ASSOCIATED WITH DIFFERENTIAL ACCUMULATION OF ASCITES IN HIGH GRADE SEROUS OVARIAN CANCER: A SEARCH FOR TARGETED THERAPY TO CONTROL ASCITES
Tomer Feigenberg 1; Carl Virtanen 2; Michelle Letarte 3; Marcus Bernardini 4; Blaise Clarke 5; Theodore Brown 6; Barry Rosen 4; K. Joan Murphy 4
1University of Toronto; 2UHN Microarray Centre; 3Hospital for Sick Children and Department of Immunology, University of Toronto; 4Department of Obstetrics and Gynecology, Division of Gyn-Oncology University Health Network (UHN); 5Department of Pathology, University Health Network (UHN); 6Department of Obstetrics and Gynecology, University Health Network (UHN) and Mt. Sinai Hospital; Toronto, ON, Canada

OC-03.04 PARP INHIBITORS IN THE TREATEMENT OF OVARIAN CANCER
Hubert Fleury 1; Euridice Carmona 1; Diane Provencher 1; Elliot Drobetsky 2; Anne-Marie Mes-Masson 1
1Centre de recherche du Centre hospitalier de l’Université de Montréal, Institut du cancer de Montréal; 2Centre de recherche de l’Hôtel Rosemont; Montreal, QC, Canada

OC-03.05 ASCITES-DERIVED PRIMARY CANCER CELL CULTURES AS A MODEL TO TEST TARGETED THERAPIES IN PATIENTS WITH ADVANCED OVARIAN CANCER
Xuan Bich Trinh 1; Magdalena Bachvarova 1; Jean-François Pelletier 1; Jean Grégoire 2; Marie-Claude Renaud 2; Alexandra Sebastianelli 2; Marie Plante 2; Dimcho Bachvarov 1
1Cancer Research Centre, Hôpital l’Hôpital-Dieu de Québec, Centre hospitalier universitaire de Québec; 2Gynecological Oncology Division, Hôpital l’Hôpital-Dieu de Québec; 3Department of Molecular Medicine, Université Laval; Quebec, QC, Canada
MONDAY, MAY 28

OC-03.06
DECREASED SEVERITY OF OVARIAN CANCER IN HENS FED FLAXSEED: ANTI-INFLAMMATORY ACTIONS TARGET E-CADHERIN (CDH1), MIR200A AND ZEB1

Karen Hales; Sheree Speckman; Buck Hales
Southern Illinois University School of Medicine, Carbondale, IL, United States

OC-03.07
COMBINED INHIBITION OF AKT ACTIVITY AND AUTOPHAGY SYNERGISTICALLY REDUCES EPITHELIAL OVARIAN CANCER SPHEROID CELL SURVIVAL

Rohann Correa; Gabriel DiMattia; Trevor Shepherd
The University of Western Ontario, London, ON, Canada

OC-03.08
PHARMACOLOGICAL TARGETING OF MAMMALIAN TARGET OF RAPAMYCIN (MTOR) INHIBITS OVARIAN GRANULOSA CELL TUMOR GROWTH

Charlène Rico 1; Marie-Noëlle Laguë 1; Mayra Tsoi 1; Aurore Dodelet-Devillers 1; Vikas Kumar 1; Mariènè Paquet 2; Marie-Eve Nadeau 1; Derek Boerboom 1
1 Faculté de Biomédecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, QC, Canada; 2McGill University, Montreal, QC, Canada

OC-03.09
CHARACTERIZATION OF MUCINOUS OVARIAN TUMORS: ASSESSING THE PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF HER2 AMPLIFICATION AND OTHER BIOMARKERS AS A STEP TOWARDS MOLECULAR TARGETED THERAPY

Jessica N. McAlpine 1; Henry Porter 1; M.C. Tolcher 2; Blaise Clarke 3; Michael S. Anglesio 4; Sambasivarao Damaraju 5; Jamie Bakkum-Gaméz 2; Steve E. Kalloger 1; David Bowtell 6; David G. Huntsman 4; C. Blake Gilks 1
1 University of British Columbia, Vancouver, BC, Canada; 2Mayo Clinic, Rochester, MN, United States; 3University of Toronto, Toronto, ON, Canada; 4Centre for Translational and Applied Genomics, Vancouver, BC, Canada; 5University of Alberta, Edmonton, AB, Canada; 6Peter MacCallum Cancer Center, Melbourne, Australia

18:15-18:30 DISCUSSION FORUM: UNITED CRITERIA FOR TISSUE AND DATA BANKING

19:00-23:00 CONFERENCE PARTY - DINE-AROUND
TUESDAY, MAY 29

07:30-08:30
CONTINENTAL BREAKFAST IN THE POSTER AREA

08:30-12:30
SYMPOSIUM IV

OVARIAN CANCER GENETICS AND EPIGENETICS: FROM THE LAB TO THE CLINIC
Co-Chairs:
Brad Nelson, M.D., Gynecologic Oncology Division, Université Laval, Quebec, QC, Canada
Helen Mackay, M.D., Centre hospitalier de l’Université de Montréal, Montreal, QC, Canada

08:30-09:00
EPIGENETIC THERAPIES TO OVERCOME OVARIAN CANCER DRUG RESISTANCE
Kenneth P. Nephew, Ph.D., Indiana University School of Medicine, Indianapolis, IN, United States

09:00-09:30
THE ROLE OF DNA DEMETHYLATION IN CANCER
Moshe Szyf, Ph.D., McGill University, Montreal, QC, Canada

09:30-10:00
DNA METHYLATION ALTERATIONS IN OVARIAN CANCER: IMPACT ON CANCER INITIATION, PROGRESSION AND RESPONSE TO THERAPY
Dimcho R. Bachvarov, Université Laval, Quebec, QC, Canada

10:00-10:30
NOVEL TARGETED AGENTS IN OVARIAN CANCER
Amit M. Oza, B.Sc., MBBS, M.D., FRCPC, FRCP, Princess Margaret Hospital, Toronto, ON, Canada

10:30-11:00
COFFEE BREAK

11:00-12:30
OC-04
SELECTED ORAL PRESENTATIONS FROM SCIENTIFIC ABSTRACTS

OC-04.01
OVARIAN CANCER SURVIVAL FOR WOMEN WITH A BRCA1 OR BRCA2 MUTATION
Joel Moody 1; John McLaughlin 1; Barry Rosen 2; Harvey Risch 3; Isabel Fan 1;
Patricia Shaw 4; Steven Narod 5
1Samuel Lunenfeld Research Institute, Toronto, ON, Canada; 2Department of Gynecology, Princess Margaret Hospital, Toronto, ON, Canada; 3Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, United States; 4Department of Pathology, Princess Margaret Hospital, Toronto, ON, Canada; 5Women’s College Research Institute, Toronto, ON, Canada
TUESDAY, MAY 29

OC-04.02 RIBOSOME BIOGENESIS AS A NOVEL TARGET OF ANTI-CANCER DRUGS
Tom Moss; Nourdine Hamdane; Frédéric Lessard; Victor Stefanovsky
Cancer Research Centre, Université Laval, Quebec, QC, Canada

OC-04.03 FUNCTIONS OF PALB2 IN GENOMIC STABILITY: IMPLICATIONS FOR BREAST AND OVARIAN CANCER
Jean-Yves Masson; Joris Pauty; Rémi Buisson
Université Laval, Cancer Research Center, Quebec, QC, Canada

OC-04.04 HIGH GRADE SEROUS CARCINOMAS WITH OVARIAN AND ENDOMETRIAL INVOLVEMENT: ASSESSMENT OF CLINICAL CHARACTERISTICS, IMMUNOPHENOTYPE, AND SITE OF ORIGIN, AS A STEP TOWARDS A BETTER CLASSIFICATION SYSTEM
Mina Wesa 1; Osama Al-Agha 2; Shannon Salvador 2; Steve E. Kalloger 2; Jen Santos 2; David G. Huntsman 2; C. Blake Gilks 2; Jessica N. McAlpine 2
1Gyn/Obs, Division of Gynecology Oncology, University of British Columbia and BCCA; 2University of British Columbia; Vancouver, BC, Canada

OC-04.05 OVARIAN CANCER ASCITES INCREASE MCL-1 EXPRESSION THROUGH THE ERK1/2-ELK1 SIGNALING TO ATTENUATE TRAIL-INDUCED APOPTOSIS
Nadzeya Goncharenko Khaider; Denis Lane; Claudine Rancourt; Alain Piché
Université de Sherbrooke, Sherbrooke, QC, Canada

OC-04.06 THE 5’-AMP-ACTIVATED PROTEIN KINASE (AMPK) PATHWAY IS UPREGULATED IN OVARIAN CANCER SPHEROIDS TO PROMOTE THE DORMANT PHENOTYPE
Teresa Peart; Rohann Correa; Gabriel DiMattia; Trevor Shepherd
University of Western Ontario, London, ON, Canada

12:30-13:00 LUNCH BREAK
TUESDAY, MAY 29

13:00-14:30  POSTER SESSION III

NEW THERAPIES IN ANIMAL MODELS AND HUMANS, CLINICAL TRIAL REPORTS, SURGICAL OUTCOMES, SURVIVAL, PSYCHOSOCIAL ISSUES

P.03  ANTI-VEGF-A THERAPY REDUCES TUMOR GROWTH AND EXTENDS SURVIVAL IN A MURINE MODEL OF OVARIAN GRANULOSA CELL TUMORS
Mayra Tsoi 1; Marie-Noëlle Laguë 2; Alexandre Boyer 2; Marièle Paquet 3; Marie-Ève Nadeau 2; Derek Boerboom 2
Faculty of Veterinary Medicine, Université de Montréal, Saint-Hyacinthe, QC, Canada; 2Université de Montréal, Saint-Hyacinthe, QC, Canada; 3McGill University, Montreal, QC, Canada

P.06  OSTEOPROTEGERIN (OPG) CONTRIBUTES TO CELL SURVIVAL IN OVARIAN CANCER
Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Département de microbiologie et infectiologie, FMSS, Université de Sherbrooke, Sherbrooke, QC, Canada

P.09  TARGETING ESTROGEN RECEPTOR ALPHA IN HORMONE-DEPENDENT OVARIAN CANCER USING NOVEL ESTRADIOL-PLATINUM(II) HYBRIDS
Kevin Brasseur; Véronique Leblanc; François Fabi; Sophie Parent; Caroline Descôteaux; Gervais Bérubé; Éric Asselin
Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada

P.12  THE CHOLESTEROL BIOSYNTHETIC PATHWAY MEDIATES THE INCREASED TUMORIGENICITY OF METASTATIC EPITHELIAL OVARIAN CANCER CELLS
James Greenaway; Rebecca Smith; Jim Petrik
University of Guelph, Guelph, ON, Canada

P.15  EMT TRANSCRIPTION FACTORS, SNAIL AND SLUG, CONTRIBUTE TO CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER
Alexandria Haslehurst 1; Madhuri Koti 1; Moyez Dharsee 2; Joseph Geraci 2; Johanne Weberpals 3; Jeremy Squire 1; Paul Park 1; Harriet Feilotter 1
Queen's University, Kingston, ON, Canada; 2Ontario Cancer Biomarker Network, Toronto, ON, Canada; 3Division of Gynecologic Oncology, The Ottawa Hospital, Ottawa, ON, Canada
P.18 MECHANISMS OF RESISTANCE IN CARBOPLATIN, DOCETAXEL, AND COMBINED CARBOPLATIN/DOCETAXEL RESISTANT OVARIAN CANCER CELL LINES
Rashmi Narendrula 1; Stephen Armstrong 1; Baoqing Guo 2; Amadeo Parissenti 2; Stephanie Cull 2; Carita Lanner 3
1Laurentian University; 2Health Sciences North Cancer Centre; 3Northern Ontario School of Medicine; Sudbury, ON, Canada

P.21 MECHANISMS BY WHICH ESTROGEN ACCELERATES OVARIAN TUMOR INITIATION
Nhung Vuong; Elizabeth Macdonald; Barbara Vanderhyden
University of Ottawa, Ottawa, ON, Canada

P.24 INCIDENCE AND PROGNOSTIC IMPACT OF HER-3 MRNA AND PROTEIN EXPRESSION IN OVARIAN CARCINOMA PATIENTS TREATED WITH PLATINUM AND PACLITAXEL
Stefan Kommos 1; Steve Kalloger 1; Boris Winterhoff 3; Christine Chow 3; Blake Gilks 1; David Huntsman 4; Michael Anglesio 1
1Department of Pathology and Lab Medicine, University of British Columbia, Vancouver, BC, Canada; 2Mayo Clinic, Department of Gynecologic Surgery, Rochester, MN, United States; 3GPEC Lab Department of Pathology of VGH and UBC, Vancouver, BC, Canada; 4CTAG, BCCA and Department of Pathology and Lab Medicine, University of British Columbia, Vancouver, BC, Canada

P.27 INDUCTION OF EPITHELIAL-MESENCHYMAL TRANSITION IN MOUSE OVODUCTAL EPITHELIAL CELLS ENHANCES STEM CELL CHARACTERISTICS
Kholoud Alwosaibai; Barbara Vanderhyden
Cellular and Molecular Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON, Canada

P.30 THE NEW AMINOSTEROID LOT 25B HAS AN IN VITRO AND IN VIVO ANTICANCER ACTIVITY ON THE OVARIAN CANCER CELL LINE OVCAR-3
Lucie Carolle Kenmogne; Jenny Roy; René Maltais; Donald Poirier
Laboratory of Medicinal Chemistry, CHUQ/CHUL-Research Center and Faculty of Medicine, Université Laval, Quebec, QC, Canada
TUESDAY, MAY 29

P.33

INVESTIGATING THE MECHANISMS FOR RESTRICTIVE MYXOMA VIRUS-MEDIATED ONCOLYSIS IN EPITHELIAL OVARIAN CANCER SPHEROIDS

Jessica Tong 1; Grant McFadden 2; Gabriel DiMattia 1; Trevor Shepherd 1

1University of Western Ontario, London, ON, Canada; 2University of Florida, Gainesville, FL, United States

P.36

SURVIVORSHIP IN OVARIAN CANCER: A PILOT STUDY TO ASSESS THE DIVERSE NEEDS OF OVARIAN CANCER SURVIVORS

Flora F. Teng 1; Barbara Yermen 2; Lisa J. Boretta 2; Elaine Chan 2; Janice M. Hu 2; Karen Sill 2; Tracy Kolwich 2; Elisabeth Ross 2; Lori A. Brotto 1; Jessica N. McAlpine 1

1University of British Columbia, Vancouver, BC, Canada; 2Ovarian Cancer Canada, Toronto, ON, Canada; 3BC Cancer Agency; Vancouver, BC, Canada

P.39

AN INTERIM ANALYSIS OF THE CANADIAN OVARIAN CANCER SURVIVORSHIP SURVEY

Steve E. Kalloger 1; Elisabeth Ross 2; Paul Hoskins 3; Anna Tinker 3

1University of British Columbia, Vancouver, BC, Canada; 2Ovarian Cancer Canada, Toronto, ON, Canada; 3British Columbia Cancer Agency, Vancouver, BC, Canada

P.42

SUPPRESSED OPA1 PROCESSING AND MITOCHONDRIAL FISSION IN OVARIAN CANCER CELLS

Bao Kong 1; Ella Fung 2; Heidi McBride 3; Ruth Slack 2; Benjamin Tsang 2

1University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2University of Ottawa, Ottawa, ON, Canada; 3McGill University, Montreal, QC, Canada

P.45

THE DIAGNOSTIC UTILITY OF P53/P16 TO DISTINGUISH HIGH-GRADE FROM LOW-GRADE SEROUS CARCINOMA

Martin Köbel 1; Alon Altman 2; Gregg Nelson 3; Guangming Han 1

1University of Calgary, Calgary, AB, Canada; 2Winnipeg Health Sciences Center, Winnipeg, MB, Canada; 3Tom Baker Cancer Centre, Calgary, AB, Canada

P.48

TANDEM INHIBITION OF C-MET, C-SRC, THE EPIDERMAL GROWTH FACTOR (EGFR) AND INDUCTION OF DNA DAMAGE: A NOVEL APPROACH TO DRUG DISCOVERY AGAINST ADVANCED OVARIAN CANCER

Ruba Halaoui; Anne-Laure Larroque-Lombard; Suman Rao; Bertrand Jean-Claude

McGill University, Montreal, QC, Canada
TUESDAY, MAY 29

14:30-15:45  DISCUSSION FORUM ON ENDOMETRIAL AND OVARIAN CANCERS: SIMILAR MOLECULAR PATHWAYS, DIFFERENT GEOGRAPHY

Moderator: David G. Huntsman

Marcus Bernardini M.D., Assistant Professor, Gynecologic Oncology, University Health Network, Toronto, ON, Canada

Clinical Challenge of Endometrial Cancer

Martin Köbel M.D., Assistant Professor, Pathology and Lab Medicine, Calgary Laboratory Services and University of Calgary

Ovarian and Endometrial Pathology - The Strengths and Insufficiencies of the Current Taxonomy and Clinical and Molecular Correlates

David G. Huntsman, M.D., FRCP, FCCM, University of British Columbia, Vancouver, BC, Canada, Interim Director, OvCaRe, BC

Clear Cell and Endometrioid Carcinoma of the Ovary - Are these Uterine Cancers in the Wrong Place: Implications and Opportunities

15:45-16:30  WORKSHOP REPORTS, SUMMARY AND FUTURE DIRECTIONS, AWARDS AND FAREWELL
INDEX OF PRESENTERS
### A

<table>
<thead>
<tr>
<th>Name</th>
<th>First Name</th>
<th>Last Name</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alvarez</td>
<td>Ronald</td>
<td>D.</td>
<td>Monday</td>
<td>14:30</td>
</tr>
<tr>
<td>Alwosaibai</td>
<td>Kholoud</td>
<td></td>
<td>Tuesday</td>
<td>13:00</td>
</tr>
<tr>
<td>Anglesio</td>
<td>Michael</td>
<td></td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Arcand</td>
<td>Suzanna</td>
<td></td>
<td>Monday</td>
<td>12:00</td>
</tr>
</tbody>
</table>

### B

<table>
<thead>
<tr>
<th>Name</th>
<th>First Name</th>
<th>Last Name</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bachvarov</td>
<td>Dimcho</td>
<td>R.</td>
<td>Tuesday</td>
<td>09:30</td>
</tr>
<tr>
<td>Backman</td>
<td>Stephanie</td>
<td></td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Bayani</td>
<td>Jane</td>
<td></td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Beauchamp</td>
<td>Marie-Claude</td>
<td></td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Bélanger</td>
<td>Moria</td>
<td>H.</td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Bernardini</td>
<td>Marcus</td>
<td></td>
<td>Tuesday</td>
<td>14:30</td>
</tr>
<tr>
<td>Birch</td>
<td>Ashley</td>
<td>H.</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Brasseur</td>
<td>Kevin</td>
<td></td>
<td>Tuesday</td>
<td>13:00</td>
</tr>
</tbody>
</table>

### C

<table>
<thead>
<tr>
<th>Name</th>
<th>First Name</th>
<th>Last Name</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caceres G.</td>
<td>Katia</td>
<td>Y.</td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Campbell</td>
<td>Ian G.</td>
<td></td>
<td>Sunday</td>
<td>14:00</td>
</tr>
<tr>
<td>Carey</td>
<td>Mark</td>
<td></td>
<td>Sunday</td>
<td>15:15</td>
</tr>
<tr>
<td>Chaudhry</td>
<td>Parvesh</td>
<td></td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Chehade</td>
<td>Rania</td>
<td></td>
<td>Monday</td>
<td>10:20</td>
</tr>
<tr>
<td>Correa</td>
<td>Rohann</td>
<td></td>
<td>Monday</td>
<td>15:50</td>
</tr>
</tbody>
</table>

**Note:**

- Local times are provided.
- Days of the week are specified.
- Dates are indicated as Monday, Tuesday, etc.
- Times are given in 24-hour format.
- Pages are denoted as P.27, P.22, etc.
- OC codes are OC-01.05, OC-02.01, OC-03.07.
<table>
<thead>
<tr>
<th>Name</th>
<th>Last Name</th>
<th>Time</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Davis</td>
<td>Sally</td>
<td>Sunday 15:15</td>
<td>OC-01.01</td>
</tr>
<tr>
<td>de Ladurantaye</td>
<td>Manon</td>
<td>Monday 12:00</td>
<td>P.56</td>
</tr>
<tr>
<td>del Carmen Mendez</td>
<td>Maria</td>
<td>Monday 12:00</td>
<td>P.44</td>
</tr>
<tr>
<td>Diaz-Hernandez</td>
<td>Veronica</td>
<td>Sunday 17:40</td>
<td>P.31</td>
</tr>
<tr>
<td>Dolman</td>
<td>Lena</td>
<td>Monday 12:00</td>
<td>P.11</td>
</tr>
<tr>
<td>Feigenberg</td>
<td>Tomer</td>
<td>Monday 15:50</td>
<td>OC-03.03</td>
</tr>
<tr>
<td>Fleury</td>
<td>Hubert</td>
<td>Monday 15:50</td>
<td>OC-03.04</td>
</tr>
<tr>
<td>Fu</td>
<td>Yang Xin</td>
<td>Monday 10:20</td>
<td>OC-02.04</td>
</tr>
<tr>
<td>Gambaro</td>
<td>Karen</td>
<td>Sunday 15:15</td>
<td>OC-01.07</td>
</tr>
<tr>
<td>George</td>
<td>Sophia H.L.</td>
<td>Monday 12:00</td>
<td>P.50</td>
</tr>
<tr>
<td>Giannakouros</td>
<td>Panagiota</td>
<td>Monday 12:00</td>
<td>P.05</td>
</tr>
<tr>
<td>Goncharenko Khaider</td>
<td>Nadzeya</td>
<td>Tuesday 11:00</td>
<td>OC-04.05</td>
</tr>
<tr>
<td>Gotlieb</td>
<td>Walter</td>
<td>Monday 15:00</td>
<td></td>
</tr>
<tr>
<td>Greenaway</td>
<td>James</td>
<td>Tuesday 13:00</td>
<td>P.12</td>
</tr>
<tr>
<td>Greenwood</td>
<td>Celia M.T.</td>
<td>Sunday 17:40</td>
<td>P.34</td>
</tr>
<tr>
<td>Griesman</td>
<td>Josh</td>
<td>Sunday 17:40</td>
<td>P.52</td>
</tr>
<tr>
<td>Halaoui</td>
<td>Ruba</td>
<td>Tuesday 13:00</td>
<td>P.48</td>
</tr>
<tr>
<td>Hales</td>
<td>Karen</td>
<td>Monday 15:50</td>
<td>OC-03.06</td>
</tr>
<tr>
<td>Haslehurst</td>
<td>Alexandria</td>
<td>Tuesday 13:00</td>
<td>P.15</td>
</tr>
<tr>
<td>Haw</td>
<td>Robin</td>
<td>Sunday 15:15</td>
<td>OC-01.06</td>
</tr>
<tr>
<td>Name</td>
<td>Speaker</td>
<td>Day and Time</td>
<td>Page</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------</td>
<td>-----------------------</td>
<td>------</td>
</tr>
<tr>
<td>Hodgkinson</td>
<td>Kendra</td>
<td>Sunday 17:40</td>
<td>P.25</td>
</tr>
<tr>
<td>Hunter</td>
<td>Sally</td>
<td>Sunday 15:15</td>
<td>OC-01.04</td>
</tr>
<tr>
<td>Huntsman</td>
<td>David G.</td>
<td>Monday 13:30, Tuesday 14:30</td>
<td></td>
</tr>
<tr>
<td>J-K</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeannotte</td>
<td>Lucie</td>
<td>Monday 10:20</td>
<td>OC-02.02</td>
</tr>
<tr>
<td>Kalloger</td>
<td>Steve E.</td>
<td>Tuesday 13:00</td>
<td>P.39</td>
</tr>
<tr>
<td>Keita</td>
<td>Mamadou</td>
<td>Monday 12:00</td>
<td>P.32</td>
</tr>
<tr>
<td>Kellenberger</td>
<td>Lisa</td>
<td>Monday 12:00</td>
<td>P.08</td>
</tr>
<tr>
<td>Kenmogne</td>
<td>Lucie Carolle</td>
<td>Tuesday 13:00</td>
<td>P.30</td>
</tr>
<tr>
<td>Kerr</td>
<td>Amanda</td>
<td>Monday 12:00</td>
<td>P.20</td>
</tr>
<tr>
<td>Kőbel</td>
<td>Martin</td>
<td>Tuesday 13:00, 14:30</td>
<td>P.45</td>
</tr>
<tr>
<td>Kommoss</td>
<td>Stefan</td>
<td>Tuesday 13:00</td>
<td>P.24</td>
</tr>
<tr>
<td>Kong</td>
<td>Bao</td>
<td>Tuesday 13:00</td>
<td>P.42</td>
</tr>
<tr>
<td>Kurman</td>
<td>Robert J.</td>
<td>Monday 08:30</td>
<td></td>
</tr>
<tr>
<td>L</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lane</td>
<td>Denis</td>
<td>Tuesday 13:00</td>
<td>P.06</td>
</tr>
<tr>
<td>Lau</td>
<td>Angela</td>
<td>Monday 12:00</td>
<td>P.38</td>
</tr>
<tr>
<td>Le Page</td>
<td>Cécile</td>
<td>Sunday 17:40</td>
<td>P.01</td>
</tr>
<tr>
<td>Leung</td>
<td>Felix</td>
<td>Sunday 17:40</td>
<td>P.43</td>
</tr>
<tr>
<td>Levine</td>
<td>Douglas A.</td>
<td>Sunday 13:30</td>
<td></td>
</tr>
<tr>
<td>Liang</td>
<td>Yao Yun</td>
<td>Monday 12:00</td>
<td>P.55</td>
</tr>
<tr>
<td>M</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Madore</td>
<td>Jason</td>
<td>Monday 12:00</td>
<td>P.35</td>
</tr>
<tr>
<td>Mamadou</td>
<td>Keita</td>
<td>Monday 12:00</td>
<td>P.32</td>
</tr>
<tr>
<td>Masson</td>
<td>Jean-Yves</td>
<td>Tuesday 11:00</td>
<td>OC-04.03</td>
</tr>
<tr>
<td>Name</td>
<td>Last Name</td>
<td>Day</td>
<td>Time</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
<td>-----------</td>
<td>-------------------</td>
</tr>
<tr>
<td>Matte</td>
<td>Isabelle</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>McAlpine</td>
<td>Jessica N.</td>
<td>Monday</td>
<td>15:50</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tuesday</td>
<td>13:00</td>
</tr>
<tr>
<td>McConchey</td>
<td>Melissa K.</td>
<td>Sunday</td>
<td>15:15</td>
</tr>
<tr>
<td>Mes-Masson</td>
<td>Anne-Marie</td>
<td>Sunday</td>
<td>17:00</td>
</tr>
<tr>
<td>Meunier</td>
<td>Liliane</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Milea</td>
<td>Anca</td>
<td>Sunday</td>
<td>15:15</td>
</tr>
<tr>
<td>Moody</td>
<td>Joel</td>
<td>Tuesday</td>
<td>11:00</td>
</tr>
<tr>
<td>Moss</td>
<td>Tom</td>
<td>Tuesday</td>
<td>11:00</td>
</tr>
<tr>
<td>Musrap</td>
<td>Natasha</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Naora</td>
<td>Honami</td>
<td>Monday</td>
<td>09:00</td>
</tr>
<tr>
<td>Narendrula</td>
<td>Rashmi</td>
<td>Tuesday</td>
<td>13:00</td>
</tr>
<tr>
<td>Nelson</td>
<td>Brad</td>
<td>Monday</td>
<td>10:20</td>
</tr>
<tr>
<td>Nephew</td>
<td>Kenneth P.</td>
<td>Tuesday</td>
<td>08:30</td>
</tr>
<tr>
<td>Oza</td>
<td>Amit M.</td>
<td>Tuesday</td>
<td>10:00</td>
</tr>
<tr>
<td>Peart</td>
<td>Teresa</td>
<td>Tuesday</td>
<td>11:00</td>
</tr>
<tr>
<td>Pelletier</td>
<td>Jean-François</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Petrik</td>
<td>Jim</td>
<td>Monday</td>
<td>15:50</td>
</tr>
<tr>
<td>Piché</td>
<td>Alain</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Rafehi</td>
<td>Samah</td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Rico</td>
<td>Charlène</td>
<td>Monday</td>
<td>15:50</td>
</tr>
<tr>
<td>Last Name</td>
<td>First Name</td>
<td>Day</td>
<td>Time</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Sawicki</td>
<td>Janet A.</td>
<td>Monday</td>
<td>14:00</td>
</tr>
<tr>
<td>Shathasivam</td>
<td>Premalatha</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Shepherd</td>
<td>Trevor</td>
<td>Monday</td>
<td>13:30</td>
</tr>
<tr>
<td>Smith</td>
<td>Kerri</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Stewart</td>
<td>Jocelyn</td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Szyf</td>
<td>Moshe</td>
<td>Tuesday</td>
<td>09:00</td>
</tr>
<tr>
<td>Tchakarska</td>
<td>Guergana</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Tone</td>
<td>Alicia</td>
<td>Monday</td>
<td>12:00</td>
</tr>
<tr>
<td>Tong</td>
<td>Jessica</td>
<td>Tuesday</td>
<td>13:00</td>
</tr>
<tr>
<td>Tonin</td>
<td>Patricia N.</td>
<td>Sunday</td>
<td>14:30</td>
</tr>
<tr>
<td>Trinh</td>
<td>Xuan Bich</td>
<td>Monday</td>
<td>15:50</td>
</tr>
<tr>
<td>Trudel</td>
<td>Dominique</td>
<td>Monday</td>
<td>10:20</td>
</tr>
<tr>
<td>Tsoi</td>
<td>Mayra</td>
<td>Tuesday</td>
<td>???????</td>
</tr>
<tr>
<td>Vanderhyden</td>
<td>Barbara</td>
<td>Monday</td>
<td>09:30</td>
</tr>
<tr>
<td>Vuong</td>
<td>Nhung</td>
<td>Tuesday</td>
<td>13:00</td>
</tr>
<tr>
<td>Wang</td>
<td>Zhiqiang</td>
<td>Sunday</td>
<td>17:40</td>
</tr>
<tr>
<td>Wesa</td>
<td>Mina</td>
<td>Tuesday</td>
<td>11:00</td>
</tr>
<tr>
<td>Wiegand</td>
<td>Kimberly</td>
<td>Monday</td>
<td>15:50</td>
</tr>
<tr>
<td>Zhang</td>
<td>Christine</td>
<td>Monday</td>
<td>12:00</td>
</tr>
</tbody>
</table>
DELEGATE DIRECTORY
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City, Province</th>
<th>Contact Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alhujaily, Ms. Ensaf</td>
<td>University of Ottawa</td>
<td>Ottawa, ON</td>
<td>T: 613-883-1678, <a href="mailto:ealhejaily@gmail.com">ealhejaily@gmail.com</a></td>
</tr>
<tr>
<td>Alvaraz, Dr. Ronald D.</td>
<td>University of Alabama</td>
<td>Birmingham, AL, United States</td>
<td><a href="mailto:Ronald.Alvarez@ccc.uab.edu">Ronald.Alvarez@ccc.uab.edu</a></td>
</tr>
<tr>
<td>Anglesio, Dr. Michael</td>
<td>BC Cancer Agency</td>
<td>Vancouver, BC</td>
<td>T: 604-877-6000, <a href="mailto:manglesio@bccrc.ca">manglesio@bccrc.ca</a></td>
</tr>
<tr>
<td>Arcand, Ms. Suzanna</td>
<td>Research Institute of the MUHC</td>
<td>Montreal, QC</td>
<td>T: 514-934-1934, ext. 44201, <a href="mailto:suzanna.arcand@mail.mcgill.ca">suzanna.arcand@mail.mcgill.ca</a></td>
</tr>
<tr>
<td>Auersperg, Dr. Nelly</td>
<td>University of British Columbia</td>
<td>Vancouver, BC</td>
<td>T: 604-736-4758, <a href="mailto:auersper@interchange.ubc.ca">auersper@interchange.ubc.ca</a></td>
</tr>
<tr>
<td>Bachvarov, Dr. Dimcho</td>
<td>Université Laval</td>
<td>Quebec, QC</td>
<td>T: 418-525-4444, ext. 15590, <a href="mailto:dimtcho.bachvarov@crhdq.ulaval.ca">dimtcho.bachvarov@crhdq.ulaval.ca</a></td>
</tr>
<tr>
<td>Backman, Dr. Stephanie</td>
<td>University of Toronto</td>
<td>Toronto, ON</td>
<td>T: 647-210-1926, <a href="mailto:stephanie.backman@utoronto.ca">stephanie.backman@utoronto.ca</a></td>
</tr>
<tr>
<td>Bairati, Prof. Isabelle</td>
<td>Université Laval</td>
<td>Quebec, QC</td>
<td>T: 418-525-4444, <a href="mailto:isabelle.bairati@chuq.qc.ca">isabelle.bairati@chuq.qc.ca</a></td>
</tr>
<tr>
<td>Barrès, Mrs. Véronique</td>
<td>Institut du cancer de Montréal</td>
<td>Montréal, QC</td>
<td>T: 514-890-8000, x 24647, <a href="mailto:veronique.barres@gmail.com">veronique.barres@gmail.com</a></td>
</tr>
<tr>
<td>Bartlett, Prof. John</td>
<td>Ontario Institute for Cancer Research</td>
<td>Toronto, ON</td>
<td>T: 647-259-4251, <a href="mailto:john.bartlett@oicr.on.ca">john.bartlett@oicr.on.ca</a></td>
</tr>
<tr>
<td>Batchvarova, Mrs. Magdalena</td>
<td>CHUQ-Centre de recherche-HDQ</td>
<td>Quebec, QC</td>
<td>T: 418-525-4444, ext. 24651, <a href="mailto:magdalenab3@hotmail.com">magdalenab3@hotmail.com</a></td>
</tr>
<tr>
<td>Bayani, Ms. Jane</td>
<td>University of Toronto</td>
<td>Toronto, ON</td>
<td>T: 416-586-4800, ext. 8813, <a href="mailto:jane.bayani@utoronto.ca">jane.bayani@utoronto.ca</a></td>
</tr>
<tr>
<td>Beaupré-Lazure, Ms. Monique</td>
<td>Ovarian Cancer Canada</td>
<td>Montreal, QC</td>
<td>T: 514-369-2972, <a href="mailto:mbeaulazare@ovariancanada.org">mbeaulazare@ovariancanada.org</a></td>
</tr>
<tr>
<td>Belanger, Ms. Moria</td>
<td>McGill University</td>
<td>Montreal, QC</td>
<td>T: 438-380-5778, <a href="mailto:moria.belanger@mail.mcgill.ca">moria.belanger@mail.mcgill.ca</a></td>
</tr>
<tr>
<td>Bernardini, Dr. Marcus</td>
<td>University Health Network</td>
<td>Toronto, ON</td>
<td>T: 416-946-2254, <a href="mailto:marcus.bernardini@uhn.on.ca">marcus.bernardini@uhn.on.ca</a></td>
</tr>
<tr>
<td>Birch, Mrs. Ashley</td>
<td>McGill University</td>
<td>Montreal, QC</td>
<td>T: 514-750-5021, <a href="mailto:ashley.birch@mail.mcgill.ca">ashley.birch@mail.mcgill.ca</a></td>
</tr>
<tr>
<td>Brasseur, Mr. Kevin</td>
<td>Université du Québec à Trois-Rivières</td>
<td>Trois-Rivières, QC</td>
<td>T: 819-376-5011, x 3359, <a href="mailto:kevin.brasseur@uqtr.ca">kevin.brasseur@uqtr.ca</a></td>
</tr>
<tr>
<td>Brown, Prof. Theodore</td>
<td>University of Toronto</td>
<td>Toronto, ON</td>
<td>T: 416 586-4800, x 2696, <a href="mailto:brown@lunenfeld.ca">brown@lunenfeld.ca</a></td>
</tr>
</tbody>
</table>
Caceres, Mrs. Katia
Institut du cancer de Montréal
Montréal, QC
T: 514-890-8000, x 24647
ky.caceres@gmail.com

Campbell, Dr. Ian
Peter MacCallum Cancer Centre
Melbourne, Australia
ian.campbell@petermac.org

Carmona, Dr. Euridice
Institut du cancer de Montréal
Montréal, QC
T: 514-890-8000, x 26397
euricarmona@gmail.com

Castonguay, Dr. Vincent
Hôtel-Dieu-de-Québec Hospital
Quebec, QC
T: 418-691-5226
vincent.castonguay1@ulaval.ca

Champoux, Mrs. Louise
Institut du cancer de Montréal
Montréal, QC
T: 514-890-8000, x 25493
louise.champoux3@sympatico.ca

Chan, Dr. Gabriel
Hôpital Maisonneuve Rosemont
Montréal, QC
T: 514-252-3400, x 3217
gabriel.chan@umontreal.ca

Chehade, Ms. Rania
Campbell Family Institute for Breast Cancer Research
Toronto, ON
T: 416-425-5684
rania.chehade@utoronto.ca

Chêne, Dr. Gautier
Institut du cancer de Montréal
Montréal, QC
T: 514-890-8000, x 25491
chenegautier@yahoo.fr

Chiasson, Ms. Emilie
Ovarian Cancer Canada
Halifax, NS
T: 902-404-7070, x 1
echiasson@ovariancanada.org

Cinq Mars, Mrs. Karen
Ovarian Cancer Canada
Toronto, ON
T: 416-962-2700, x 230
kcinqmars@ovariancanada.org

Collins, Mrs. Olga
OHRI
Ottawa, ON
T: 613-260-5575
ocollins@ohri.ca

Crosley, Mr. Powel
Granulosa Cell Tumour Research Foundation
Edmonton, AB
T: 780-801-2646
powel@ualberta.ca

Davis, Ms. Sally
Peter MacCallum Cancer Centre
East Melbourne, ON
T: 396-561-936
sally.davis@petermac.org

de Ladurantaye, Mrs. Manon
Institut du cancer de Montréal
Montréal, QC
T: 514-890-8000, x 25491
madel13@yahoo.com

Díaz-Hernandez, Dr. Veronica
Universidad Nacional Autónoma de Mexico
Mexico City
roveazdh@yahoo.com.mx

DiMattia, Dr. Gabriel
London Regional Cancer Centre
London, ON
T: 519-685-8600, x 53625
dimattia@uwo.ca

Dolman, Ms. Lena
McGill University
Montreal, QC
T: 514-934-1934, x 44281
lena.dolman@mail.mcgill.ca

Doré, Dr. Jules
Memorial University of Newfoundland
St. John’s, NL
T: 709-777-8573
jdore@mun.ca
Dorward, Dr. Ann
Memorial University of Newfoundland
St. John's, NL
T: 709-777-6662
ann.dorward@mun.ca

Dupont, Ms. Chanel
Université Laval
Quebec, QC
T: 418-525-4444
chanel.dupont.1@ulaval.ca

Ellard, Dr. Susan
BCCA-Southern Interior
Kelowna, BC
T: 250-712-3996
sellard@bccancer.bc.ca

Feigenberg, Dr. Tomer
University of Toronto
Toronto, ON
T: 647-963-7195
tomer.feigenberg@uhn.ca

Fleury, Mr. Hubert
Institut du cancer de Montréal
Montréal, QC
T: 514-890-8000, x 26397
fleury.hu@gmail.com

Fu, Dr. Yang Xin
University of Alberta
Edmonton, AB
T: 780-248-1363
yangxin@ualberta.ca

Gambaro, Dr. Karen
McGill University
Montreal, QC
T: 514-934-1934, x 44201
karen.gambaro@mail.mcgill.ca

Garson, Dr. Kenneth
Ottawa Hospital Research Institute
Ottawa, ON
T: 613-737-8899, x 75205
kgarson@ohri.ca

George, Dr. Sophie
Campbell Family Institute for Cancer Research
Ajax, ON
T: 647-836-5501
sophiahlg@gmail.com

Gervais, Dr. Thomas
École Polytechnique de Montréal
Montréal, QC
T: 514-340-4711, x 3752
thomas.gervais@polymtl.ca

Giannakouros, Ms. Panagiota
Université de Sherbrooke
Sherbrooke, QC
T: 819-993-9227
p.giannakouros@usherbrooke.ca

Gilkis, Dr. Blake
University of British Columbia
Vancouver, BC
T: 604-875-4901
blake.gilkis@vch.ca

Goncharenko Khai...
Hales, Dr. Karen  
Southern Illinois University  
Carbondale, IL  
T: 618-453-1548  
khales@siumed.edu

Haslehurst, Ms. Alexandria  
Queen’s University  
Kingston, ON  
T: 613-533-2000, x 74894  
9ah33@queensu.ca

Haw, Dr. Robin  
OICR  
Toronto, ON  
T: 647-260-7985  
robin.haw@oicr.on.ca

Helpman, Dr. Limor  
Tel Aviv, Israel  
Cambridge, MA  
T: 972-52-7360367  
lhelpm an@gmail.com

Hirte, Dr. Hal  
Juravinski Cancer Centre  
Hamilton, ON  
T: 905-387-9495  
hal.hirte@jcc.hhsc.ca

Hodgkinson, Ms. Kendra  
University of Ottawa  
Ottawa, ON  
T: 613-230-5507  
kendra.hodgkinson@gmail.com

Hunter, Dr. Sally  
Peter McCallum Cancer Centre  
Melbourne, Victoria  
T: 61-3-96561950  
sally.hunter@petermac.org

Huntsman, Dr. David  
University of British Columbia  
Vancouver, BC  
T: 604-877-6000  
dhuntsma@bccancer.bc.ca

Jeannotte, Prof. Lucie  
Université Laval  
Quebec, QC  
T: 418-525-4444, x 15552  
lucie.jeannotte@crhdq.ulaval.ca

Kalloger, Mr. Steve  
University of British Columbia  
Vancouver, BC  
T: 604-875-4273  
skalloger@me.com

Karakasis, Ms. Katherine  
Princess Margaret Hospital  
Toronto, ON  
T: 416-946-5503  
katherine.karakasis@uhn.ca

Kellenberger, Ms. Lisa  
University of Guelph  
Guelph, ON  
T: 519-780-7253  
lkellenb@uoguelph.ca

Kendall-Dupont, Mrs. Jennifer  
Institut du cancer de Montréal  
Montréal, QC  
T: 514-890-8000, x 25502  
jen.kendalldupont@gmail.com

Kemogne, Ms. Lucie Carolle  
Université Laval-CRCHUQ/CHUL  
Quebec, QC  
T: 418-525-4444, x 42296  
Lucie-Carolle.Kemogne@crchuq.ulaval.ca

Kerr, Ms. Amanda  
University of Guelph  
Guelph, ON  
T: 519-824-4120, x 58261  
akerr01@uoguelph.ca

Kolwich, Ms. Tracy  
Ovarian Cancer Canada  
Vancouver, BC  
T: 604-676-3431  
tkolwich@ovariancanada.org

Kommoss, Dr. Stefan  
BC Cancer Agency  
Vancouver, BC  
T: 604-877-6000  
skommoss@bccrc.ca

Kong, Mr. Bao  
University of Ottawa  
Ottawa, ON  
T: 613-798-5555, x 13713  kong099@gmail.com

Kurman, Dr. Robert  
Johns Hopkins Hospital  
Baltimore, MA, United States  
rkurman@jhmi.edu

Lane, Mr. Denis  
Université de Sherbrooke  
Sherbrooke, QC  
T: 819-820-6868, x 15859  
denis.lane@Usherbrooke.ca
Lanner, Dr. Carita  
Northern Ontario School of Medicine  
Sudbury, ON  
T: 705-662-7238  
carita.lanner@nosm.ca  

Lawson, Dr. Christine  
UCSD Moores Cancer Center  
La Jolla, CA  
T: 858-822-0556  
clawson@ucsd.edu  

LePage, Dr. Cécile  
Institut du cancer de Montréal  
Montréal, QC  
T: 514-890-8000, x 25502  
cecilelepage@yahoo.ca  

Leung, Mr. Felix  
University of Toronto  
Toronto, ON  
T: 416-586-4800, x 8813  
felix.leung@mail.utoronto.ca  

Levine, Douglas  
Sloan-Kettering Institute for Cancer Research  
New York, NY  
levine2@mskcc.org  

Macdonald, Mrs. Elizabeth  
OHRI  
Alexandria, ON  
T: 613-525-5040  
elmacdonald@ohri.ca  

Mackay, Dr. Helen  
University of Toronto  
Toronto, ON  
T: 516-946-2253  
helen.mackay@uhn.on.ca  

Madore, Mr. Jason  
BC Cancer Agency  
Vancouver, BC  
T: 604-877-6000  
jmadore@bccrc.ca  

Mamadou, Mr. Keita  
Université Laval  
Quebec, QC  
T: 418-525-4444, x 24651  
mamadou.keita.1@ulaval.ca  

Masson, Dr. Jean-Yves  
Université Laval Cancer Research Center  
Quebec, QC  
T: 418-525-4444, x 15154  
Jean-Yves.Masson@crhdq.ulaval.ca  

Matte, Ms. Isabelle  
Université de Sherbrooke  
Sherbrooke, QC  
T: 819-820-6868, x 15859  
isabelle.matte@usherbrooke.ca  

McAlpine, Dr. Jessica  
UBC and BCCA  
Vancouver, BC  
T: 604-875-5608  
jessica.mcalpine@vch.ca  

McConchy, Ms. Melissa  
BC Cancer Agency  
Vancouver, BC  
T: 604-877-6000  
MMcConchy@bccancer.bc.ca  

Mendez, Dr. Carmen  
Universidad Nacional Autonoma de Mexico  
Mexico City  
T: 55-56587759  
carmenmnh2001@yahoo.com.mx  

Mes-Masson, Dr. Anne-Marie  
Institut du cancer de Montréal  
Montréal, QC  
T: 514-890-8000, x 25496  
anne-marie.mes-masson@umontreal.ca  

Meunier, Mrs. Liliane  
Institut du cancer de Montréal  
Montréal, QC  
T: 514-890-8000, x 24647  
liliane.meunier@gmail.com  

Miller, Dr. Dianne  
University of British Columbia  
Vancouver, BC  
T: 604-875-4268  
dianne.miller@vch.ca  

Moody, Dr. Joel  
Samuel Lunenfeld Research Institute  
Mississauga, ON  
T: 416-567-3776  
moody@lunenfeld.ca  

Morin, Mrs. Chantale  
Université Laval  
St-Nicolas, QC  
T: 418-496-1105  
chantale.morin.1@ulaval.ca
Moss, Prof. Tom  
Université Laval  
Quebec, QC  
T: 418-691-5281  
tom.moss@crhdq.ulaval.ca

Musrap, Ms. Natasha  
University of Toronto  
Toronto, ON  
T: 416-586-4800, x 8813  
natasha.musrap@utoronto.ca

Nachtingal, Prof. Mark  
University of Manitoba  
Winnipeg, MB  
T: 204-789-3708  
mark_nachtingal@umanitoba.ca

Naora, Dr. Honami  
The University of Texas MD Anderson Cancer Center  
Houston, TX, United States  
hnaora@mdanderson.org

Narendrula, Ms. Rashmi  
Laurentian University  
Sudbury, ON  
T: 705-662-7238  
RZ_Narendrula@laurentian.ca

Nelson, Dr. Brad  
BC Cancer Agency  
Victoria, BC  
T: 250-519-5700  
bnelson@bccancer.bc.ca

Nephew, Dr. Kenneth  
Indiana University School of Medicine  
Indianapolis, IN, United States  
T: 812-855-9445  
knephew@indiana.edu

Oza, Dr. Amit  
University Health Network  
Toronto, ON  
T: 416-946-2818  
amit.oza@uhn.on.ca

Peart, Ms. Teresa  
University of Western Ontario  
London, ON  
T: 519-685-8500, x 53626  
tpeart@uwo.ca

Pedernera, Dr. Enrique  
Universidad Nacional Autonoma de Mexico  
Mexico City  
epa@servidor.unam.mx

Pelletier, Mr. Jean-François  
Université Laval  
Lévis, QC  
T: 418-833-5051  
jean-francois.pelletier.7@ulaval.ca

Perri, Dr. Sabrina R.  
Amgen Canada  
Montreal, QC  
T: 514-528-9830  
sperri@amgen.com

Petrik, Dr. Jim  
University of Guelph  
Guelph, ON  
T: 519-824-4120, x 54921  
jprik@uoguelph.ca

Piché, Dr. Alain  
Université de Sherbrooke  
Sherbrooke, QC  
T: 819 564-5321  
alain.piche@usherbrooke.ca

Pilon, Ms. Michelle  
Ovarian Cancer Canada  
Calgary, AB  
T: 1-866-591-6622  
mipilon@ovariancanada.org

Plante, Dr. Marie  
Université Laval  
Quebec, QC  
T: 418-525-4444, x 15734  
Marie.Plante@crhdq.ulaval.ca

Press, Dr. Joshua  
McGill University  
Montreal, QC  
T: 514-880-1817  
joshua.press@mcgill.ca

Provencher, Dr. Diane  
Institut du cancer de Montréal  
Montréal, QC  
T: 514-890-8000, x 27244  
diane.provencher.chum@ssss.gouv.qc.ca

Quinn, Dr. Michael  
Institut du cancer de Montréal  
Montréal, QC  
T: 514-890-8000, x 24647  
mcjquinn@gmail.com
Rafehi, Ms. Samah  
University of Western Ontario  
London, ON  
T: 519-204-4153  
srafehi@uw o.ca

Rico, Dr. Charlène  
Faculté de BioMédecine Vétérinaire  
Saint Hyacinthe, QC  
T: 450-773-8521  
charlene.m.rico@orange.fr

Ringuette, Dr. Maurice  
University of Toronto  
Toronto, ON  
T: 416-978-6955  
maurice.ringuette@utoronto.ca

Ross, Ms. Elisabeth  
Ovarian Cancer Canada  
Toronto, ON  
T: 416-962-2700  
eross@ovariancanada.org

Rottapel, Dr. Robert  
Ontario Cancer Institute  
Toronto, ON  
T: 416-581-7852  
rottapel@uhnres.utoronto.ca

Sapsford, Ms. Marilyn  
Ovarian Cancer Canada  
Toronto, ON  
T: 416-962-2700, x 231  
msapsford@ovariancanada.org

Sawicki, Dr. Janet A.  
Thomas Jefferson University  
Philadelphia, PA, United States  
sawickij@mlhs.org

Shathasivam, Ms. Premalatha  
SLRI, Mount Sinai Hospital  
Toronto, ON  
T: 416-586-4800, x 5601  
shathasivam@lunenfeld.ca

Shepherd, Dr. Trevor  
The University of Western Ontario  
London, ON  
T: 519-685-8500, x 56347  
tshephe6@uw o.ca

Spybey, Ms. Thomasina  
University of Toronto  
Toronto, ON  
T: 416-586 4800, x 5601  
spybey@lunenfeld.ca

Stewart, Ms. Jocelyn  
Ontario Cancer Institute  
Toronto, ON  
T: 416-788-3300  
jocelyn.stewart@utoronto.ca

Szyf, Dr. Moshe  
McGill University  
Montreal, QC  
moshe.szyf@mcgill.ca

Tchakarska, Dr. Guergana  
Institut du cancer de Montréal  
Montreal, QC  
T: 514-890-8000, x 24647  
gtchakarska@gmail.com

Thériault, Dr. Brigitte  
Ontario Cancer Institute  
Toronto, ON  
T: 416-946-4483  
brigitte.theriault@gmail.com

Tone, Dr. Alicia  
BC Cancer Agency  
Vancouver, BC  
T: 604-675-8000  
atone@bccrc.ca

Tong, Ms. Jessica  
University of Western Ontario  
London, ON  
T: 519-913-9727  
jtong23@uw o.ca

Tonin, Ms. Patricia  
McGill University  
Montreal, QC  
T: 514-934-1934, x 44069  
patricia.tonin@mcgill.ca

Trinh, Dr. Xuan Bich  
Hôtel-Dieu de Québec  
Quebec, QC  
T: 418-446-6998  
bich@telenet.be

Trudel, Dr. Dominique  
University Health Network  
Montréal, QC  
T: 647-317-6001  
dtrudel@uhnres.utoronto.ca

Tsoi, Ms. Mayra  
University of Montreal  
St-Hyacinthe, QC  
T: 450-250-4520  
may_t15@hotmail.com
Vanderhyden, Prof. Barbara  
Ottawa Hospital Research Institute  
Ottawa, ON  
T: 613-737-7700, x 70330  
bvanderhyden@ohri.ca

Virtanen, Mr. Carl  
University Health Network  
Toronto, ON  
T: 416-581-7433  
cvirtane@uhnresearch.ca

Vuong, Ms. Nhung  
University of Ottawa  
Ottawa, ON  
T: 613-795-3473  
rosevuong@gmail.com

Wang, Mr. Zhiqiang  
Université Laval  
Quebec, QC  
T: 418-525-4444, x 24659  
zhiqiang.wang.1@ulaval.ca

Wesa, Dr. Mina  
University of British Columbia  
Vancouver, BC  
T: 604-723-3243  
minawesa@gmail.com

Wiegand, Ms. Kimberly  
BC Cancer Agency  
Vancouver, BC  
T: 604-877-6000  
kwiegand@cw.bc.ca

Woo, Ms. Michelle  
BC Cancer Agency  
Vancouver, BC  
T: 604-675-8000  
miwoo@bccrc.ca

Yasmeen, Dr. Amber  
Segal Cancer Center  
Montreal, QC  
T: 514-340-8222, x 2979  
amber.yasmeen@mail.mcgill.ca

Zhang, Dr. Christine  
York University  
Richmond Hill, ON  
T: 647-637-9879  
christine.zhang.a@gmail.com